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ABSTRACT 
 
Understanding Weak Binding for Phospho(enol)pyruvate to the Allosteric Site of 
Phosphofructokinase from Lactobacillus delbrueckii subspecies bulgaricus. 
(August 2011) 
Scarlett Blair Ferguson, B.S., Angelo State University  
Chair of Advisory Committee: Dr. Gregory D. Reinhart 
 
Phosphofructokinase (PFK) from the lactic acid bacterium Lactobacillus 
delbrueckii subspecies bulgaricus (LbPFK) is a non-allosteric PFK with weak binding 
affinity for both the allosteric ligands phospho(enol)pyruvate (PEP) and magnesium 
adenosine diphosphate (MgADP).  PEP and MgADP bind to the same allosteric binding 
site but exhibit opposite effects, PEP acting as an inhibitor and MgADP an activator.  In 
2005, Parichatttanakul, et al. solved the first crystal structure of LbPFK to 1.87 Å 
resolution and allowed for a structural comparison of LbPFK to the allosteric forms of 
PFK from E. coli (EcPFK) and Bacillus stearothermophilus (BsPFK).  Two additional 
structures of LbPFK have been determined with the first having phosphates bound at the 
four active sites and four allosteric sites solved to 2.20 Å resolution.  The second 
structure solved to 1.83 Å resolution contains phosphates at all eight sites with the 
addition of the substrate fructose-6-phosphate (F6P) in the active sites.  These structures 
are similar to the published sulfate-bound LbPFK structure. Overall, the secondary, 
tertiary and quaternary structure is conserved with the exception of the residues in the 
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allosteric site.  E55, H59, S211, D214, H215 and G216, as well as the long cassettes of 
residues 52-61 (PFKs1) and 206-218 (PFKs2) were mutated to the corresponding 
residue/residues in Thermus thermophilus PFK (TtPFK).  PFKs1 and PFKs1 were also 
combined to form PFKs1s2.  The single mutations along with PFKs1 and PFKs2 showed 
no enhancement in PEP binding, but PFKs1s2 enhanced PEP binding 10-fold with no 
change in MgADP binding compared to LbPFK. 
 D12, located along the active site interface 15 Å away from the allosteric site, 
was mutated to an alanine and exhibited enhanced binding 9-fold for both PEP and 
MgADP to the allosteric binding site.  A crystal structure of D12A was solved to 2.30 Å 
resolution with sulfate bound to all eight binding sites, and showed no major changes in 
secondary, tertiary or quaternary structure when compared to the sulfate-bound wild-
type LbPFK structure.  Combining D12A with PFKs1s2 (PFKs1s2/D12A) further 
enhanced PEP binding with a 21-fold tighter binding compared to LbPFK with MgADP 
binding being similar to D12A.  PEP inhibition was also quantitated in PFKs1s2/D12A 
with a Qay = 0.007 ± 0.0008.  Coupling between PEP and F6P in PFKs1s2D12A is 2-
fold stronger than the coupling measured in EcPFK and 7-fold stronger than the coupling 
measured in BsPFK.  The coupling measured in PFKs1s2D12A is the first measured in 
any of the LbPFK variants. 
 
 
 
 
 v 
DEDICATION 
 
To my parents and husband: Terry and Mellissa Blair and Brent Ferguson.  Mom 
and Dad, I could not have done any of this without your continued love and support.  
You always taught me to believe in myself, work hard to achieve my goals and to be 
thankful for the many blessings my God has given me.  Thank you for providing a home 
for me to escape to, for always being there to listen about the ups and downs of graduate 
school and for your unconditional love.  Because of all you have done for me, for which 
I am truly grateful, I dedicate this dissertation to my parents. 
Brent, you are the love of my life and the most loving, gentle and patient man I 
have ever known.  Your never-ending love and support have made this process a success 
and the last seven years would not have been the same without you in my life.  Meeting 
you was the best thing that ever happened to me and without you I don’t think I could 
have made it through the toughest times.  God has blessed me by giving me a wonderful 
husband who is not only an amazing scientist but a great listener and friend.  Your 
continued support and advice have made me a better person and scientist.  For all this, I 
dedicate this work to my husband.     
 
 
 
 
 
 vi 
ACKNOWLEDGEMENTS 
 
I would first like to thank my advisor, Dr. Gregory D. Reinhart, for his support, 
guidance and patience throughout my graduate career.  He is an amazing mentor and 
never gave up on me even when my experiments just wouldn’t work.  Thanks to all my 
committee members, past and present, for all the advice and support over the last eight 
years.  Dr. Scholtz has been a constant figure throughout my graduate career and has 
always pushed me to be my best.  Dr. Fitzpatrick and Dr. Kladde helped me start out and 
helped me through my preliminary exams.  Dr. Panin and Dr. Pettigrew stepped in to be 
a part of my committee when I needed them the most.  All together my committee 
members helped me become the scientist I am today.  I would also like to thank Dr. 
Sacchettini and Dr. Reddy for their work and help in solving the crystal structures of 
LbPFK discussed in chapters III and V of this dissertation. 
Thanks to my lab mates, past and present, for great conversations and making the 
lab a great place to work.  To the many friends I have made over the last eight years, you 
are all amazing people and I am a better person for having all of you in my life.  Thanks 
for making me laugh, being by my side when times were tough and helping me celebrate 
all the accomplishments along the way.  Thanks to my family for all being such a great 
support system and praying for me over the years.  Mom, thanks for helping me move in 
the heat of August, for the many visits and for always answering the phone to hear about 
my day.  Dad, thanks for all the advice you have given me about life and science.  You 
are a brilliant person and have taught me so much during my life.  Brent, thanks for 
 vii 
marrying me and loving me with all your heart.  You are the love of my life and an 
amazing scientist.  I would like to thank Sam, Tracy and Jordan Fulton for being 
wonderful friends and giving me a place to sleep these last few months.  You guys are 
great and have always been there to help Brent and me over the years.  
Last but certainly not least, I want to thank my God for blessing me with the 
knowledge to make it through graduate school, the family and friends to support me, and 
a wonderful husband.  Thanks for listening to the many prayers and I give you all the 
glory for accomplishments I have achieved.   
 viii 
NOMENCLATURE 
 
ABC ATP binding cassette 
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CcpA Catabolite control protein A 
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L. Lactococcus 
LAB Lactic acid bacteria 
LB Lysogeny broth 
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Lb. Lactobacillus 
LbPFK PFK from Lactobacillus delbrueckii subspecies bulgaricus 
LDH Lactate dehydrogenase  
MOPS 3-[N-Morpholino] Propanesulfonic acid 
MWC Monod-Wyman-Changeux 
NAD+ Nicotinamide adenine dinucleotide, oxidized form 
NADH Nicotinamide adenine dinucleotide, reduced form 
NADP+ Nicotinamide adenine dinucleotide phosphate, oxidized form 
NADPH Nicotinamide adenine dinucleotide phosphate, reduced form 
nH Hill coefficient 
PAGE  Polyacrylamide Gel Electrophoresis 
PDB Protein Data Bank 
PEP Phospho(enol)pyruvate 
PFK Phosphofructokianse 
PFKs1 Residues 52-61 of LbPFK substituted by 52-61 of TtPFK 
PFKs2 Residues 206-218 of LbPFK substituted by 206-218 of TtPFK 
PFKs1s2 Combination of PFKs1 and PFKs2 
Pi Inorganic phosphate 
pI Isoelectric point 
PG Phosphoglycolate 
PKP Phosphoketolase pathway 
PMF  Proton motive force 
 x 
PPi Pyro-phosphate 
PPi-PFK Pyro-phosphate dependent PFK 
PTS PEP-dependent phosphotransferase system 
PYK Pyruvate kinase 
S. Streptococcus 
SDS Sodium Dodecyl Sulfate 
TIM Triose-phosphate isomerase 
Tris Tris [Hyroxymethyl] aminomethane 
TtPFK PFK from Thermus thermophilus 
 [A] Concentration of substrate 
[E] Concentration of free enzyme 
[X] Concentration of effector, MgADP 
[Y] Concentration of effector, PEP 
[EA] Concentration of enzyme-substrate complex 
[XE] Concentration of enzyme-effector complex 
[XEA] Concentration of ternary complex 
Kia° Dissociation constant for A in the absence of X 
Kia∞ Dissociation constant for A in the saturating presence of X 
Kix° Dissociation constant for X in the absence of A 
Kix∞ Dissociation constant for X is the saturating presence of A 
Kiy° Dissociation constant for Y in the absence of A 
Qax Coupling constant between substrate and effector X 
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Qay Coupling constant between substrate and effector Y 
K1/2 Concentration of F6P at half-maximal velocity 
Kb Dissociation constant for substrate B 
ν Initial velocity 
Vmax Maximal velocity 
ΔGa ° Free Energy of F6P binding 
ΔGy ° Free Energy of PEP binding 
Kiyapp Apparent dissociation constant for effector Y 
Kixapp Apparent dissociation constant for effector X 
KiPEP Dissociation constant for PEP in absence of MgADP 
kcat Catalytic turnover number 
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CHAPTER I 
INTRODUCTION: LACTIC ACID BACTERIAL SUGAR METABOLISM AND THE 
ROLE OF PHOSPHOFRUCTOKINASE 
  
 Phosphofructokinase (PFK) from the lactic acid bacteria (LAB) Lactobacillus 
delbrueckii subspecies bulgaricus (Lb. delbrueckii subspecies bulgaricus), or LbPFK, is 
a non-allosteric form of PFK.  Compared to allosteric forms of PFK from E. coli 
(EcPFK) and Bacillus stearothermophilus (BsPFK) LbPFK is similar in both sequence 
and overall structure.  Only the residues within the allosteric site are significantly 
different.  These differences might explain the weak binding for the allosteric ligands, 
the inhibitor phospho(enol)pyruvate (PEP) and the activator MgADP.  In order to get a 
better understanding of the lack of allosteric regulation of PFK in Lb. delbrueckii 
subspecies bulgaricus, a review of sugar metabolism in LAB is given below.    
 
Sugar Transport in Lactic Acid Bacteria    
 LAB are a heterogeneous group of microorganisms that have one thing in 
common; they produce lactic acid as the end product of carbohydrate fermentation (1).  
They are gram-positive bacteria that can be found in the shape of rods or cocci and share 
many biochemical, physiological and genetic characteristics.  These bacteria as a whole 
are acid-tolerant, catalase-negative, non-spore forming, facultative anaerobes with low 
GC content in their DNA.  In addition, LAB are heterotrophic chemoorganotrophs, that  
 ____________ 
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is they use pre-formed organic carbon for both a source of carbon and energy.  There are 
two pathways of fermentation in LAB, homofermentation and heterofermentation.  In 
homofermentation, lactic acid is produced from 90% of the sugar metabolized but in 
heterofermentation, acetic acid, ethanol and carbon dioxide are produced in addition to 
lactic acid.  LAB generally possess one pathway or the other but examples of certain 
species being able to switch between the two exist (2). 
 These bacteria are mostly found in nutrient-rich environments including dairy 
products, meat products, vegetables, plants and cereals as well as the gastrointestinal and 
genitourinary tracts of animals and humans.  The specific environment that they inhabit 
plays a huge role in their overall metabolism and genetic make-up (1, 2).  It is the 
specific genetic make-up which classifies them into twelve distinct genera.  Eight of 
these twelve (Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, 
Streptococcus, Tetragenococcus and Enterococcus) are used directly in the fermentation 
of food.  These eight can further be divided based on the fermentation pathways they 
utilize.  Lactococcus, Pediococcus, Streptococcus, Tetragenococcus and Enterococcus 
are all homo-fermenters, while Leuconostoc and Oenococus are hetero-fermenters.  The 
genera Lactobacillus is different in that it contains both homo- and hetero-fermenters 
(2).   
 LAB are found in various types of nutrient-rich environments and the 
environments in which these bacteria thrive influence their overall metabolism.  LAB 
cannot obtain energy by oxidative or respiratory processes because of a lack in 
cytochrome or electron transport protein (2).  Therefore, these bacteria must get their 
 3 
energy from the production of ATP via substrate phosphorylation reactions.   The type of 
pathway used to ferment sugars is dependent on the type of fermentation utilized by the 
bacteria (Figure 1-1).  In the case of homofermentation, glycolysis is used to form 
pyruvate which is then converted into lactate via lactate dehydrogenase (LDH).   This 
pathway yields two moles of ATP per mole of hexose, that is used as an energy source, 
and one mole of NADH which must be re-oxidized by LDH in order to keep the 
[NADH]/[NAD+] ratio balanced.  An example of homofermentation is Lb. delbrueckii 
subspecies bulgaricus that is involved in the fermentation of yogurt along with 
Streptococcus thermophilus (S. thermophilus).  Lb. delbrueckii subspecies bulgaricus 
exhibits very simple metabolism only metabolizing lactose, fructose, glucose and 
mannose.  Lb. delbrueckii subspecies bulgaricus cannot metabolize galactose, formed 
from the hydrolysis of lactose.  Galactose is instead used to uptake more lactose into the 
cell and thus favors the exclusive use of glycolysis (3). 
   LAB that make use of heterofermentation use the phosphoketolase pathway 
(PKP) to metabolize hexoses.  The main difference between the PKP and glycolysis is 
the presence of aldolase.  Aldolase catalyzes the cleavage of fructose-1,6-bisphosphate 
(FBP) to form glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone-phosphate 
(DHAP).  Triose-phosphate isomerase (TIM) converts all the DHAP to G3P that then 
continues through the second half of glycolysis to produce pyruvate and 2 moles of ATP.  
In the PKP pathway, aldolase is absent and phosphoketolase is used to form G3P that 
will eventually become lactate and acetyl phosphate which can produce either acetate or 
ethanol.  In order to keep the [NADH]/[NAD+] ratio balanced, alcohol dehydrogenase 
 4 
and acetaldehyde dehydrogenase reoxidize the 2 moles of NADH which are made in the 
first half of the PKP.  Some examples of hetero-fermenters include Leuconostoc lactis 
(dairy fermentation), Lactococcus mesenteroides subspecies cremoris (vegetable 
fermentation) and Lb. sanfranciscensis (making of sourdough bread) (2).    
 One of the major ways by which LAB regulate sugar metabolism is through the 
uptake and release of carbon sources.  There are three main systems used by these 
bacteria to transport sugars across the outer membrane; the PEP-dependent 
phosphotransferase system (PTS), symport systems and ATP-binding cassette (ABC) 
systems.  The PTS is the primary way that sugars are transported and is used for highly 
metabolized sugars such as glucose (4).  Sugars that are used when glucose is low or 
absent are mostly transported using either a symport or ABC transport system.  The 
ABC transport system also known as the binding-lipoprotein-dependent transport system 
in gram positive bacteria is made up of three molecular components.  These components 
include two integral membrane proteins which function as permeases and are made up of 
6 transmembrane segments, two peripheral membrane proteins that hydrolyze ATP and a 
periplasmic or lipoprotein substrate binding protein.  Even though these transport 
systems can be used for sugars they are mostly used to transport amino acids, peptides 
and osmoprotectants (2, 5). 
 In symport systems, a membrane permease will bind the sugar substrate along 
with an ion and transport the sugar using an ion gradient.  The most common ion 
gradient in bacteria is the proton motive force (PMF), but some symport systems have 
been shown to use sodium ion gradients for transport.  Some of the sugars utilized by  
 5 
 
Figure 1-1.  Schematic of major pathways involved in hexose fermentation in lactic acid 
bacteria.  The major pathways utilized in hexose fermentation are highlighted, glycolysis 
(red) and the two phosphoketolase pathways (blue).   The main products of fermentation 
are boxed and the enzymes which make the two distinct are shown in black.  TIM = 
triose-phosphate isomerase.  Many steps in both pathways are left out for simplicity.  
This figure was adapted from (2). 
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symport systems in LAB are lactose, galactose, and xylose (2).   In the case of lactose, 
when a symport system is used for its transport, lactose is imported and then hydrolyzed 
to glucose and galactose (6, 7).  The glucose is then phosphorylated to form glucose-6-
phosphate, which proceeds through glycolysis (Figure 1-1).  Then, in most LAB, the 
galactose is converted into glucose-6-phosphate via the Leloir pathway (8).  However as 
mentioned earlier, in S. thermophilus and Lb. delbrueckii subspecies bulgaricus the 
galactose cannot be fermented and this is due to low expression of enzymes involved in 
the Leloir pathway. 
 The main transport system for highly metabolized sugars is the PTS.  This 
system is found across the bacterial kingdom and consists of three main protein 
components, EI, HPr and EII.  EI and HPr are both intracellular proteins and are found in 
all PTS systems.  EII can act as a complex containing multiple proteins or one single 
protein with multiple domains.  EII is also where the substrate specificity is located and 
is organized in one to two integral membrane domains and two intracellular, hydrophilic 
domains.  The transport in this system occurs through an in-line associative 
phosphorylation mechanism (Figure 1-2).  The first reaction is the phosphorylation of 
the EI protein by PEP forming P~EI and pyruvate.  The steps that follow include the 
phosphoryl transfer from EI to HPr, HPr to EIIA, EIIA to EIIBC and finally from EIIBC 
to the sugar substrate.  The phosphorylated sugar can then enter either glycolysis or the 
PKP for fermentation.  Each of these phosphoryl transfers occur via a direct interaction 
between the proteins.  The residues involved in these interactions as well as those 
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involved in phosphorylation have been widely studied (4).  In LAB, PTS sugar transport 
provides a very efficient means for the regulation of sugar metabolism. 
 The way in which the PTS system regulates sugar metabolism is via carbon 
catabolite repression (CCR).  CCR is defined as the ability of certain sugars within the 
growth conditions to effect the gene expression or the activity of enzymes within the cell 
involved in the catabolism of other sugars (4).  CCR is different between gram-negative 
and gram-positive bacteria depending on the presence/absence of certain proteins.  In 
gram-negative bacteria, the main regulatory protein is EIIA which regulates sugar 
transport by means of its phosphorylation state.  In gram-positive bacteria it is HPr that 
regulates sugar transport via its phosphorylation state.  Each of these proteins allows for 
the transport of a PTS sugar to affect the transport of a non-PTS sugar.  
 In gram-negative bacteria, the phosphorylation of EIIA via HPr regulates sugar 
transport.  In an environment where a highly metabolized sugar such as glucose is 
present, the PTS system is activated and EIIA is phosphorylated by HPr that in turn 
phosphorylates EIIB.  EIIB then subsequently phosphorylates the sugar (Figure 1-2).  
Unphosphorylated EIIA can then bind and inhibit various enzymes including the lactose 
permease, melibiose permease, ATP-hydrolyzing component of the maltose transport 
system and glycerol kinase (9-14).  These enzymes are involved in the transport of non-
PTS sugars and the binding of unphosphorylated EIIA prevents the induction of the 
genes involved in the uptake and metabolism of these non-PTS sugars in a process 
known as inducer exclusion.  When bacteria are put into a less enriched environment, the 
PTS system is not needed but is replaced by other transport systems.  EIIA stays  
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Figure 1-2.  Regulation of sugar transport and metabolism in lactic acid bacteria.  
Highlighted are three transport systems for uptake of PTS-sugars, lactose and maltose.  
For PTS sugars, the transfer of phosphate from PEP to EI, EI to HPr, HPr to EIIA, and 
finally EIIA to EIIBC, allows the sugar to enter the cell and become phosphorylated.  
The sugar then enters glycolysis forming FBP as one of the intermediates.  FBP can 
affect the activity of HPrK/P (HPr kinase/phosphatase) which can either phosphorylate 
or dephosphorylate HPr are serine 46.  Phosphorylation at this position can cause HPr to 
bind CcpA and this complex can bind to the cre element of DNA and effect 
transcription.  Depending on the location of the cre element, in reference to the promoter 
regions which are indicated by the -10 or -35, depends on whether binding of the 
CcpA/HPr complex causes activation or repression of transcription.  P-Ser-HPr can also 
interact with non-PTS transport systems such as the maltose transporter by binding to its 
intracellular components.  HPr phosphorylation at His15 at the active site can also 
regulate non-PTS lactose uptake through the phosphorylation of the EIIA involved in 
glucose uptake (EIIAGlc).  The EIIAGlc will interact with the LacS membrane protein and 
stimulate the exchange of lactose for galactose.  This figure was adapted from (4).  
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phosphorylated thus relieving the inhibition of the enzymes mentioned above along with 
the activation of adenylate cyclase.  When EIIA is phosphorylated it can directly bind to 
and activate adenylate cyclase thus forming cAMP.  cAMP can then bind to the cAMP 
binding protein (Crp) that interacts with DNA recognition sites and affects transcription 
of certain genes.  Genes affected by the binding of cAMP/Crp include adenylate cyclase, 
Crp, EIIA as well as an E. coli repressor Mlc, that binds to EIIBC and therefore affects 
PTS transport.  Binding of cAMP/Crp represses the transcription of adenylate cyclase 
but activates the transcription of genes for Crp, EIIA and Mlc.  Increasing the 
concentration of EIIA, Crp and Mlc would allow for the cell to be prepared in the case 
where it is once again put into a nutrient rich environment.  Overall this regulation helps 
the bacteria to survive in multiple types of environments, from nutrient-rich to nutrient-
depleted. 
 The presence of metabolites can also affect sugar transport in gram-negative 
bacteria.  The concentrations of PEP and pyruvate affect the phosphorylation state of 
EIIA and the ratio of PEP to pyruvate changes when cells are grown in different 
environments.  In the absence of glucose, the PEP/pyruvate ratio is between 3-10 but 
adding glucose to the media causes the ratio decrease to 0.12 in 15 sec (15).  The drop in 
the PEP/pyruvate ratio indicates that the PTS system is being utilized in the presence of 
glucose.  The amount of phosphorylated EIIA is dependent on the PEP/pyruvate ratio in 
that the lower the ratio the lower the amount of phosphorylated EIIA, another indication 
that the PTS system is being utilized.  This decrease in the amount of phosphorylated 
 10 
EIIA would increase the inhibition of the enzymes involved in the transport of non-PTS 
proteins thus slowing down the uptake of the non-PTS sugars.    
 In the case of gram-positive bacteria that have low-GC content DNA, the gene 
for adenylate cyclase is absent and HPr acts as the protein by which the regulation of 
sugar transport occurs (4).  In this type of regulation, it is not only important to consider 
the phosphorylation state of HPr but also the specific amino acid residue of HPr that is 
phosphorylated.  Under normal PTS transport, HPr is phosphorylated by EI at the active 
site H15.  This phosphorylation is dependent on the presence of PEP thus is often 
referred to as PEP-dependent phosphorylation of HPr.  The phosphate group can then be 
transferred to EIIA where it will eventually be transferred to the PTS sugar or under non-
PTS conditions; the unphosphorylated form of EIIA can bind to other proteins and 
block/inhibit the transport of non-PTS sugars.  The latter is seen in the case of the LacS 
transporter that is involved in the uptake of lactose via the simultaneous release of 
galactose (16-18).  Unphosphorylated EIIA can also interact and inhibit glycerol kinase 
to slow down the uptake of glycerol in the cell (19, 20). 
 The other amino acid of HPr that can be phosphorylated is S46.  S46 is 
considered the regulatory site since S-46 has no involvement with phosphoryl transfer in 
the PTS and when HPr is phosphorylated at this position most of the regulation occurs.  
The phosphorylation of HPr at S46 involves an enzyme with dual activities.  The 
enzyme HPrK/P can act as a kinase as well as a phosphorylase.  As with most kinases, 
HPrK is ATP-dependent so the phosphorylation of HPf by HPrK is known as ATP-
dependent phosphorylation.  The phosphorylase activity is interesting in that it involves 
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an inorganic phosphate (Pi) and produces pyro-phosphate (PPi) (21).  The Pi can bind to 
the same site as the β-phosphate of ATP and acts as a nucleophile to attack the P~S-HPr 
to produce PPi.  This mechanism is known as phospho-phosphorolysis.  The process of 
phosphorylation of HPr at S46 is known as inducer expulsion.  Inducer expulsion is due 
to the accumulation of certain sugar phosphates in the cell that become 
dephosphorylated and expelled as soon as the bacteria are exposed to a nutrient rich 
environment.  Phosphorylation of HPr at S46 affects the phosphorylated of HPr at H15 
and vice versa (22-25) .  HPr phosphorylation is one of the ways that sugar metabolism 
is controlled in LAB. 
 As with gram-negative bacteria and EIIA, phosphorylated HPr can affect the 
transcription of certain genes.  When phosphorylated at S46, HPr can interact with the 
catabolite control protein A (CcpA), and this complex can then interact with a catabolite 
response element (cre) on DNA and affect transcription.  Cre is located in the promoter 
region or at the 5’ end of many catabolite-repressed transcription units.  The location of 
cre in reference to the promoter can lead to activation or repression of transcription of 
the downstream gene target.  If cre is located within a promoter, then binding of the 
HPr/CcpA complex will block the binding of the RNA polymerase and thus repress 
transcription.  If it binds upstream of the start site then it allows transcription of the 
specific gene to occur.  An example of this regulation is the binding of PepRI, whose 
transcriptional regulation is similar to CcpA in Lb. delbrueckii subspecies bulgaricus 
(26).  PepRI specifically interacts with the cre element upstream of the start site of pepQ 
which encodes for a dipeptidase involved in hydrolyzing X-Pro dipeptides.  PepRI can 
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also bind to the cre element of its own gene pepRI and cause auto-regulation which is 
regulated by the presence of glucose.          
 The phosphorylation of HPr at S46 is also regulated by the concentration of 
fructose-1,6-bisphosphate (FBP), an intermediate in glycolysis, ATP and Pi.  The 
metabolite control of HPr at S46 involves the antagonistic activities of the HPrK/P.  In 
some LAB, such as B. subtilis, FBP can activate the kinase activity of HprK/P but this 
effect is less pronounced in the enzyme from Lb. casei (27, 28) .  When grown in the 
presence of glucose, a highly metabolized sugar, the concentration of both FBP and PPi 
increase.  FBP activates the ATP-dependent phosphorylation of HPr but inhibits 
phosphorylation by pyrophosphate.  The activation of HPrK would favor PTS transport 
over other sugar transport system.  When the concentration of FBP decreases, the 
concentration of Pi increases and the increase in Pi would stimulate the 
dephosphorylation of HPr.  Dephosphorylation of HPr that occurs in the presence of less 
metabolized sugar such as succinate, would in turn stimulate non-PTS sugar transport.  
Regulation by PPi is not well understood but the regulation of HPr allows for the 
survival of the bacteria in numerous types of environments (21). 
 
Regulation of Glycolysis in LAB 
 As mentioned above, one of the pathways which is vital in the breakdown and 
regulation of sugar metabolism is glycolysis.  As shown in Figure 1-2, once sugars are 
imported into the cell they become phosphorylated, enter into glycolysis in the form of 
glucose-6-phosphate and eventually become pyruvate.  During homofermentation the 
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pyruvate is then converted into the final product of fermentation, lactate, via LDH.  
There are several steps within this process that are regulated and in bacteria include 
PFK, pyruvate kinase (PYK) as well as LDH.  Regulation of these enzymes can be at the 
gene level, protein level or both.  In the LAB S. mutans there is an additional location of 
regulation in glycolysis using the non-phosphorylation, NADP+-dependent G3P 
dehydrogenase, which converts G3P  to 3-phosphoglycerate bypassing phosphoglycerate 
kinase allowing for no net ATP production in glycolysis as well as the production of 
NADPH (29).  There is also evidence in Lactococcus lactis (L. lactis) of mixed 
inhibition of glyceraldehyde-3-phosphate dehydrogenase by ATP, ADP and AMP (30).  
PFK, PYK and LDH are vital in the metabolism of sugars for the majority of bacterial 
species. 
 In most bacteria, PFK, PYK and LDH are allosterically regulated by various 
ligands.  Regulation of these enzymes differs between the various species of LAB.  In 
the case of LDH, which catalyzes the conversion from pyruvate to lactate with the 
concomitant conversion of NADH to NAD+, FBP acts as an allosteric activator (31).  
LDH can be found in various forms that differ in both their regulation as well as the 
product formed from the reaction.  In some bacteria there is a single LDH that can form 
both enantiomers of lactate, while some bacteria contain a single LDH which forms a 
specific enantiomer of lactate.  LDHs that only form one enantiomer of lactate are 
normally coupled to a lactate racemase allowing for the formation of the second 
enantiomer of lactate (32).  There is also a third situation where the cell contains both 
types of LDH without needing a racemase.  For example, Lb. casei contains both types 
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of LDH with D-LDH having very low activity and L-LDH being allosterically activated 
by FBP and irreversible.  Along with allosterically activated LDHs, there are examples 
of non-allosteric versions of the enzyme within LAB.  LDH from Lb. plantarum and Lb. 
acidophilus are both non-allosteric versions of the allosteric enzyme found within Lb. 
casei and Lb. curvatus (31).  Upon comparing the non-allosteric forms with the allosteric 
forms, it was found that they shared the common quaternary structure of a homotetramer 
along with similar pI values.  The main differences were the amino acid composition at 
both the N- and C-termini as well as the overall isoleucine content.  The allosteric site 
for FBP in LAB is thought to be the anion site of the non-allosteric vertebrate enzymes 
based on sequence comparisons and this site has minor differences when comparing the 
allosteric and non-allosteric forms of the LAB LDHs (33-35).   
 PYK, another enzyme important in the regulation of glycolysis in bacteria, 
catalyzes the irreversible phosphoryl transfer from PEP to ADP forming ATP and 
pyruvate.  In eukaryotes there are two forms of PYK which differ based on the allosteric 
activation by FBP (36).  Two forms of PYK are also found in E.coli, one allosterically 
activated by FBP and the second activated by AMP and several mono-phosphate sugars 
(37, 38).  In the LAB L. lactis, PYK was found to be allosterically activated by FBP, 
inhibited by Pi and to be important in the regulation of glycolysis (39).  When LAB are 
grown in the presence of a highly metabolized sugar such as glucose, FBP 
concentrations increase allowing for the activation of PYK.  However once the cells 
were put in a glucose-deficient environment, the levels of 2-phosphoglycerate, 3-
phosphoglycerate and PEP increase and are linked to the increase in Pi which will inhibit 
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PYK (40).  The regulation of PYK in the homofermentative LAB Lb. bulgaricus is 
different from PYK in L. lactis since FBP acts as an inhibitor rather than an activator.  
The strong activators are AMP as well as glucose-6-phosphate and ribose-5-phosphate, 
which are similar to the activators known for PYK from Bacillus stearothermophilus 
(38, 41).  The difference in the regulation between Lb. bulgaricus and L. lactis PYK may 
be due to the differences in the promiscuity of sugar metabolism in each LAB. 
 The third enzyme which is important in glycolytic regulation in bacteria is PFK 
which catalyzes the phosphoryl transfer from MgATP to fructose-6-phosphate (F6P) 
forming MgADP and FBP.  In E.coli, there are two forms of PFK present in the cell.  
PFK-1is allosterically regulated by two ligands, the inhibitor PEP and the activator 
MgADP.  But as with LDH there are examples of non-allosteric and allosteric PFKs 
within LAB.  In the 1970s, several PFKs originating from LAB were analyzed for their 
ability to bind various allosteric effectors (42, 43).  Doelle concluded that PFK from Lb. 
casei and Lb. plantarum were non-allosteric enzymes as they showed no effect with 
ATP, ADP, citrate or NH4+, which are known to either effect the yeast or mammalian 
enzyme.  This study however was not performed with pure enzyme, but Lb. plantarum 
was later studied again in a comparison with PFK from Lb. acidophilus.  In this later 
study, pure enzyme was used and both PFKs were analyzed against the effectors FBP, 
NH4+, citrate, PEP, 5’-AMP as well as ADP.  PFK from Lb. plantarum was not regulated 
by any of the above effectors except NH4+ which increased the maximal velocity (Vmax) 
of the enzyme 20%.  However since this was the only effect seen among the various 
allosteric effectors, it was concluded to be a non-allosteric PFK.  In contrast, PFK from 
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Lb. acidophilus was activated by FBP and inhibited by ADP.  Both of these affected the 
Vmax of the enzyme with FBP also having an inhibitory effect on the binding of F6P.  
The inhibition by FBP and ADP could be simply due to product inhibition but the 
authors concluded that PFK from Lb. acidophilus is an allosteric PFK (42). 
 In the early 1980s the PFK from S. thermophilus was purified and studied and it 
was determined to be non-allosteric based on the inability of FBP, PEP, and ADP to 
affect the activity of the enzyme (44).  The PFK from S. thermophilus is however more 
stable at higher temperatures compared to PFK from Lb. plantarum.  Then in the early 
1990s, LbPFK was studied in detail by Jean-Renaud Garel (45, 46).  From these studies, 
it was concluded that LbPFK was a non-allosteric PFK due to the lack of inhibition by 
citrate and PEP or activation by the ADP or GDP.  Although there appears to be a lack in 
allosteric regulation of these important glycolytic enzymes there is evidence of 
regulation at the gene level. 
 In E. coli, PFK-2 is different in both structure and allosteric regulation compared 
to PFK-1 (47-50).  Structurally, PFK-1 is a homotetramer while PFK-2 is a homodimer.  
Both show inhibition by MgATP but through different mechanisms.  MgATP inhibition 
in PFK-1 is though the binding of MgATP to one active site inhibits the binding of F6P 
to another active site (51, 52).  MgATP inhibition of PFK-2 is different as binding of 
MgATP causes a structural change from dimers to tetramers that forms an additional 
binding site for MgATP (48).  In 2008, a crystal structure of PFK-2 in its tetrameric 
form was solved with two MgATP molecules bound to each monomer.  One of the 
MgATP molecules was located where the phosphoryl donor would bind with the other at 
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another site which was proposed to be an effector site (53).  Then in 2010, another 
structure was determined with F6P bound to the active site and upon comparing this 
structure to the MgATP-bound structure a model for MgATP inhibition was proposed 
(54).  It was proposed that upon binding of MgATP a conformation change occurs which 
induces a negative interplay between the binding of MgATP to the allosteric site and the 
F6P bound at the active site.  This negative coupling is accompanied by changes in both 
the K1/2 for F6P as well as in the catalytic turnover, kcat.  In PFK-1, MgATP inhibits the 
binding of F6P in addition to changing the homotropic coupling between the F6P 
binding sites (51).   
 Interestingly, a second PFK has been identified in two different strains of Lb. 
delbrueckii subspecies bulgaricus (55, 56).  Lb. delbrueckii subspecies bulgaricus is the 
only LAB so far to have acquired a second PFK and the role of this enzyme is unknown.  
It is proposed that many LAB acquire addition genes from either horizontal gene transfer 
or gene duplication (57).  Some examples of genes for which a second gene has been 
acquired in LAB are genes for various proteins involved in sugar metabolism such as 
enolase, L-LDH, and proteins from the PTS (58).  These genes can be acquired from the 
most recent ancestor or from a distant ancestor so the role of the proteins is difficult to 
determine.   
 In determining the potential identity of this second PFK from Lb. delbrueckii 
subspecies bulgaricus a sequence alignment was performed with PFK-2 from E. coli, 
PFK-1 from Lb. delbrueckii subspecies bulgaricus and E. coli as well as a 
pyrophosphate-dependent PFK (PPi-PFK) from Thermoproteus tenax which is an 
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anaerobic, hyperthermophilic archaeon (59). PFK-2 from Lb. delbrueckii subspecies 
bulgaricus showed approximately 30% sequence identity to PFK-1 from both Lb. 
delbrueckii subspecies bulgaricus and E. coli, 30% identity to PPi-PFK from 
Thermoproteus tenax and only 12% identity to PFK-2 from E. coli.   PFK-2 from Lb. 
delbrueckii subspecies bulgaricus contains 359 amino acids compared to the 319 from 
Lb. delbrueckii subspecies bulgaricus PFK-1, 309 from E. coli PFK-2 and 337 from 
Thermoproteus tenax PPi-PFK.  From the sequence comparison it is difficult to identify 
which PFK this second PFK from Lb. delbrueckii subspecies bulgaricus would be more 
closely related to but is unlikely to be a homolog of PFK-2 from E.coli due to the lack of 
sequence identity.  Further work is needed to identify the role of this second PFK in 
sugar metabolism of Lb. delbrueckii subspecies bulgaricus.  
  
Transcriptional Regulation of PFK, PYK and LDH in LAB 
 As mentioned earlier, there is strong transcriptional regulation within LAB via 
the metabolism of sugars transported by the PTS system.  In addition to the gene for 
PepRI in Lb. delbrueckii subspecies bulgaricus, the transcription of genes for PFK, PYK 
and LDH have been shown to be regulated via the transport of PTS sugars (60-64).  In L. 
lactis, the genes for PFK, PYK and LDH form one multicistronic operon called the las 
operon (65).  This is novel and is not seen in gram-negative bacteria such as E. coli, 
where these genes are unlinked.  Within the las operon is a strong codon bias, and in E. 
coli a strong correlation between the degree of codon bias and the level of gene 
expression has been demonstrated where the most highly expressed genes exhibit the 
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greatest degree of codon bias (66).  So the strong codon bias of the las operon would 
indicate that these genes are strongly expressed.  The promoter region of the las operon 
contains a cre element that allows for the regulation by CcpA, which can bind to the cre 
element and either activate or repress transcription.  For the las operon it was shown that 
the transcription of pfk, pyk and ldh was diminished when CcpA was absent from the cell 
(62).  This indicates that CcpA acts as a transcriptional activator for the las operon and 
would allow for the regulation of these genes thereby linking glycolytic regulation with 
sugar transport via the PTS system. 
 The genes for PFK and PYK are also known to form a single operon in other 
LAB such as Lb. delbrueckii subspecies bulgaricus (67), Lb. casei (64), S. thermophilus 
(61) and S. bovis (60).  Unlike L. lactis however these operons do not contain the gene 
ldh and therefore the expression of ldh is separate from those of pfk and pyk.  Within 
these homofermentative LAB there is evidence of regulation of transcription of the pfk-
pyk operon by CcpA.  In Lb. casei it has been shown that CcpA represses the 
transcription of pfk-pyk, which is opposite of the CcpA regulation in L. lactis.  The 
expression of pfk-pyk is also greater in the presence of PTS sugars such as glucose and 
lactose compared to non-PTS sugars such as ribose.  The opposite regulation of pfk-pyk 
expression by PTS sugars and CcpA would provide a way for the cell to control 
glycolytic flux in bacteria that have limited regulation at the protein level.  In S. bovis, 
the co-transcription of pfk-pyk was regulation by both the presence of PTS sugars and 
CcpA.  However, the effect of CcpA on the transcription was positive which is similar to 
that of L. lactis but opposite of Lb. casei.  The difference between the transcriptional 
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regulation of these genes within LAB may involve the differences in the 
microenvironments which these bacteria thrive along with the differences in the 
metabolic pathways which they utilize.  Also the regulation of glycolysis at the gene 
level may be in place of the limited control of these enzymes at the protein level in LAB. 
 
Allosteric Regulation of LbPFK 
 Although it is important to understand sugar metabolism and its regulation in 
LAB, the main focus of this dissertation is to understand the molecular basis for the lack 
of allosteric regulation in LbPFK.  As mentioned above, PFK from most bacteria is 
allosterically regulated but is not the case for PFK from several LAB.  Allostery is the 
phenomenon in which the binding of the substrate (K-type effect) or maximal rate of 
enzyme turnover (V-type effect) of an enzyme is affected by the binding of a ligand to a 
site other than the active site of that enzyme.  There are many examples of allosteric 
enzymes other than PFK, for example, the first allosteric enzymes studied were aspartate 
transcarbamoylase and threonine deaminase, and from these studies came two separate 
models to explain the allosteric phenomena (68, 69).  The MWC and KNF models are 
two-state models in which the enzyme can adopt two different states, the active or 
relaxed R-state and the inhibited or tense T-state (70, 71).  In the MWC model there is a 
preexisting equilibrium between the two states, and the enzyme can only be found in one 
of the two forms.  The KNF model is different in that it does not invoke a pre-existing 
equilibrium between the two states, but rather a conformational change occurs within the 
enzyme to each subunit as the allosteric ligand binds.  The KNF model allows for both 
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positive and negative cooperativity to be explained, something not considered in the 
MWC model.  However, both of these models are too simple to explain the allosteric 
phenomena of PFK (72, 73). 
 The approach we have taken in studying the allosteric regulation of PFK involves 
thermodynamic linkage analysis.  In this analysis, a single substrate-single modifier 
scheme is applied to describe the thermodynamic relationships between the binding of 
the effector (X) and the binding of the substrate (A) to the enzyme (E) (Figure 1-3) (74).  
In the absence of catalysis, Figure 1-3 can be simplified to two ligands binding to a 
single enzyme at different sites, and the dissociation constants can be defined as below 
(75, 76):                                                                    
                                                                                                    (1-1) 
                                                                                                            (1-2) 
                                                                                                       (1-3)                                               
                                                            (1-4) 
where Kia° and Kix° are the dissociation constants for the substrate and the effector in the 
absence of the other ligand, respectively.  Kia∞ and Kix∞ are the dissociation constants for 
the substrate and effector in the saturating presence of the other ligand.  Based on the 
definition of the various dissociation constants, the relationship between the dissociation 
constants for the substrate and effector is given by equation 1-5. 
                                        Kia° x Kix∞ = Kix° x Kia∞                                                 (1-5) 
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A simple rearrangement of equation 1-5 gives the ratios in equation 1-6, which define 
the coupling constant Qax which describes the coupling between the substrate and the 
effector. 
                                                           (1-6) 
 Based on the above definition, the coupling constant Qax is in itself an 
equilibrium constant which defines the disproportionation equilibrium below (77). 
                                                   (1-7) 
Through the use of Qax it is possible to determine the nature of the allosteric response as 
well as the magnitude of the response.  For example, if Qax > 1 the allosteric effector is 
an activator but if Qax < 1 the allosteric effector is an inhibitor.  If Qax = 1 there is no 
allosteric response to the effector.  Through this analysis it is possible to fully describe 
the thermodynamics parameters of the allosteric system being studied.  Since the 
allosteric response of PFK is solely a K-type effect, it is possible to study this response 
by analyzing the effect the allosteric ligand has on the binding of the substrate, F6P in 
this manner.  By measuring the change in the Michaelis constant for F6P as a function of 
X, the data can be plotted on a log-log scale and fit to the following equation to 
determine the important variables needed to fully describe the thermodynamic properties 
of the enzyme (Figure 1-4) (77). 
                   (1-8) 
where K1/2 is the concentration of F6P at half-maximal velocity.  
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Figure 1-3.  Single substrate-single modifier scheme.  Above describes the 
thermodynamic linkage between the substrate (A) and the allosteric effector (X).  E 
denotes enzyme, P denotes product, small k’s are rate constants and large K’s are 
dissociation constants defined in the text.   
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 In the case of LbPFK, where saturation with PEP could not be obtained and 
therefore a Qax could not be determined (assumes Qax =0 or infinite coupling), the 
following equation derived from equation 1-8 can be used to determine the dissociation 
constants for F6P and PEP.  
                                            (1-9)  
 Kia° and Kix° can then be compared between various PFKs in order to better 
understand the basis of the differences in the binding of ligands and allosteric regulation 
exhibited by the various bacterial PFKs (78).  This analysis has been used to study 
EcPFK and BsPFK in great detail and both of these PFKs exhibit strong inhibition by 
PEP with EcPFK also exhibiting strong activation by MgADP (72, 79, 80).  More 
previous studies on the allosteric PFK from the extremely thermophilic, gram-positive 
Thermus thermophilus (TtPFK) indicates that TtPFK is also inhibited by PEP, although 
not as strongly as EcPFK and BsPFK, and shows slight activation by MgADP.  Figure 1-
5 shows a comparison of the binding and allosteric inhibition by PEP between these 
three PFKs along with the non-allosteric LbPFK.  It is clear that the four PFKs differ not 
only in their ability to bind the inhibitor PEP but also in the extent of inhibition which is 
exhibited by PEP.  Of the four, TtPFK exhibits the tightest binding affinity for PEP at 
3µM with BsPFK exhibiting the strongest inhibition by PEP (Qay = 0.001 ± 0.001) (78, 
81).  LbPFK stands out as having very weak PEP binding, approximately 27 mM, with 
inhibition only evident at very high concentrations of PEP (82).  Due to these differences 
the sequences between the allosteric EcPFK, BsPFK and TtPFK and the non-allosteric 
LbPFK were compared. 
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Figure 1-4.  Dependence of the dissociation constant for A as a function of X.  The 
equation describing this curve is equation 1-8 in the text.   
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  Figure 1-6 shows the sequence alignment between LbPFK, TtPFK, BsPFK and 
EcPFK.  Upon inspection, it is clear that the overall sequence is well conserved with 
residues in the 230s and 240s along with the C-terminus being the least conserved.   
When comparing the four, LbPFK having 47% identity with 66% similarity  to EcPFK, 
56% identity with 74% similarity and 46% identity with 60% similarity.  Another small 
region that is well conserved between the allosteric PFKs but not in LbPFK contains 
residues 211-214, which includes 3 positively charged residues in the allosteric PFKs 
and only one in LbPFK.  The first crystal structure of LbPFK was determined at 1.86 Å 
resolution in 2005 and when residues 211-214 are mapped onto the structure, these 
residues are found within the allosteric binding site.  When this structure is compared to 
those of EcPFK and BsPFK, the allosteric site is the least conserved region within the 
enzyme (83, 84).  The allosteric site contains residues 55 and 59 and residue 55 is not 
well conserved.  Residue 59 is also not conserved with an H present in LbPFK, with the 
other allosteric PFKs having a D or N.  These differences within LbPFK could 
potentially explain the weak binding affinity for the inhibitor PEP and therefore the lack 
of allosteric inhibition.  
 In this study, the molecular basis for the weak PEP binding and lack of allosteric 
inhibition in LbPFK was examined using crystallography and site-directed mutagenesis.  
Chapter III introduces the phosphate-bound and substrate-bound structures of LbPFK 
that will allow for comparisons of the bound active site to F6P-bound EcPFK and 
BsPFK.  Chapter IV introduces the mutations D12A, T156A and H160A which are  
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Figure 1-5:  Dependence of K1/2 for F6P as a function of PEP concentration for LbPFK 
(black), EcPFK (red), BsPFK (blue) and TtPFK (purple).  The K1/2 for F6P was 
measured at various concentrations of PEP and replotted.  EcPFK, BsPFK ad TtPFK 
data were fit to equation 1-8, while LbPFK was fit to equation 1-9.  Data for EcPFK 
from (72), BsPFK (85) and TtPFK (78).    
 
 
 
 
 
 28 
 
 
Figure 1-6.  Amino acid sequence alignment between LbPFK, BsPFK, EcPFK and 
TtPFK.  The amino acid sequences were aligned using MacVectorTM 7.0.  The regions 
discussed within this dissertation are highlighted by colored boxes with the allosteric site 
residues in blue and the active site interface residues in red.  The numbering of the 
amino acid residues in the figure is according to the EcPFK sequence but in the text is 
according to  the LbPFK sequence.   
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located along the active site interface and D12A appears to play a role in the binding of 
PEP to the allosteric site 15 Å away.  The crystal structure of D12A is also introduced 
and shows no major structural changes when compared to wild-type LbPFK.  D12A has 
also been studied in BsPFK and a comparison between D12A LbPFK and D12A BsPFK 
will be discussed.  Chapter V will discuss the mutagenesis within the allosteric binding 
site of LbPFK where single as well as long cassette mutations were made in attempt to 
enhance the binding for PEP to the allosteric site.  Finally, chapter VI will introduce a 
mutant of LbPFK which contains both allosteric site mutants and D12A.  This mutant 
enhanced binding for PEP 25-fold compared to wild-type LbPFK and allowed for the 
measurement of inhibition by PEP for the first time in a non-allosteric PFK. 
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CHAPTER II 
GENERAL MATERIALS AND METHODS 
 
Materials   
All chemical reagents used in buffers, protein purifications, and enzymatic assays 
were of analytical grade and were purchased from Sigma-Aldrich (St. Louis, MO) or 
Fisher Scientific (Fair Lawn, NJ). Creatine kinase, the sodium salt of ATP and the 
ammonium sulfate suspension of glycerol-3-phosphate dehydrogenase were purchased 
from Roche (Indianapolis, IN). The ammonium sulfate suspensions of aldolase and 
triosephosphate isomerase, and the sodium salts of phosphocreatine and PEP were 
purchased from Sigma-Aldrich. The coupling enzymes were extensively dialyzed 
against 50 mM MOPS-KOH, pH 7.0, 100 mM KCl, 5 mM MgCl2, and 0.1 mM EDTA 
before use. The sodium salt of F6P was purchased from Sigma-Aldrich or USB 
Corporation (Cleveland, OH). NADH and DTT were purchased from Research Products 
International (Mt. Prospect, IL).   Mimetic Blue 1 resin used in protein purifications was 
purchased from Promatic BioSciences (Rockville, Maryland), respectively.  Site-directed 
mutagenesis was performed using the QuikChange Site-Directed Mutagenesis System 
from Stratagene (La Jolla, CA). Oligonucleotides were synthesized and purchased from 
Integrated DNA Technologies, Inc (Coralville, IA). DNA modifying enzymes and 
dNTPs were purchased from Stratagene (Cedar Creek, TX), New England Biolabs 
(Ipswich, MA), or Promega (Madison, WI). BCA Assay reagents were purchased from 
Pierce.  Deionized distilled water was used throughout. 
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Methods 
Protein Purification for WT LbPFK 
MRL277 cells containing pKK223-3/PFK were grown in LB broth in the 
presence on 0.1 mg/mL ampicillin at 37 °C to an optical density of 0.6 and then induced 
with 0.5 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) and allowed to grow at 37 
°C for an additional 5 hours.  Cells were harvested and stored at -80 °C.  The harvested 
cells were then resuspended in Buffer A (50 mM Tris-HCl pH 7.5, 0.1 mM EDTA), 
sonicated and centrifuged for 1 hour at 8,000 x g at 4 °C.  Next, the cell lysate was 
treated with DNase I for 20 minutes at 37 °C and centrifuged again for 1 hour at 8,000 x 
g at 4 °C.  The resulting cell lysate was loaded onto a pre-equilibrated Mimetic Blue I 
column, the column washed with at least 5 column volumes of Buffer A and eluted with 
a 0-2 M NaCl gradient in the same buffer.  The PFK eluted at approximately 1 M NaCl.  
Fractions containing PFK activity were pooled, dialyzed against Buffer B (50 mM Tris-
HCl pH 7.5, 0.1 M EDTA, 5 mM MgCl2) and concentrated.  Protein concentration was 
determined using the BCA protein assay and the purity was assessed with SDS-PAGE. 
 
Kinetic Analysis 
 Standard conditions for the PFK assay were pH 8.0 and 25 °C.  The PFK reaction 
was measured by coupling the production of fructose-1,6-bisphosphate to the oxidation 
of NADH and followed at 340 nm.  The reaction was initiated by adding 6 µl of PFK 
into a 600 µl reaction buffer containing Vmax Buffer (50 mM EPPS pH 8.0, 10 mM 
MgCl2, 10 mM NH4Cl, 0.1 mM EDTA), 2 mM DTT, 250 µg of aldolase, 50 µg of 
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glycerol-3-phosphate dehydrogenase, 25 µg triose-phosphate isomerase, 15 mM ATP 
and 5 mM F6P.  40 µg/mL creatine kinase and 4 mM phosphocreatine were added to the 
reaction buffer for the regeneration of MgATP from the production of MgADP.  F6P, 
MgATP, and PEP concentrations were varied as indicated.  MgATP was added as a 
solution of equal molar MgCl2 and ATP.  The rate of the reaction was measured by the 
decrease in absorbance at 340 nm as a function of time.  One unit of enzyme activity is 
defined as the amount of enzyme needed to produce 1 µmol of fructose-1,6-bisphosphate 
per minute.  
 
Data Analysis 
 Steady-state rates as a function of F6P concentration were fit to the following 
equation (86): 
                                                                                              (2-1) 
where ν equals the steady-state rate of turnover, Vmax represents the maximal activity, 
[A] equals the concentration of F6P, K1/2 is the concentration of F6P which results in 
half-maximal  activity and nH is the Hill coefficient.  When determining the kinetic 
parameters for MgATP, where the nH is 1, the following equation was used (87): 
                                                     (2-2) 
 To quantify the allosteric response of PFK to PEP in the case of allosteric 
inhibition, the K1/2 for F6P was measured at various concentrations of PEP and the 
results were fit to the following equation (74): 
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                                                (2-3) 
where Y is PEP, Kia° is the dissociation constant for F6P is the absence of PEP, Kiy° is 
the dissociation for PEP in the absence of F6P, and Qay is the coupling constant between 
PEP and F6P.  The coupling constant describes both the magnitude and nature of the 
allosteric effect (74, 88).  When Qay is greater than 1 the allosteric ligand is an activator 
and when it is less than 1 then the allosteric ligand is an inhibitor.  When Qay is equal to 
1 there is no allosteric response upon binding of the allosteric ligand.  When the binding 
of PEP is weak, as is seen in LbPFK,  and saturation of PEP at the allosteric site cannot 
be achieved, the data are instead fit to the competitive inhibition equation (89), which 
corresponds to equation 2-3 when Qay = 0.   
          (2-4) 
The free energy of binding for various ligands was determined using the following 
equation: 
                                                (2-5) 
where ΔG° is the free energy of ligand binding, R is the gas constant in kcal/mol, and T 
is the temperature in Kelvin.  In the case of other ligands the appropriate dissociation 
constant was substituted for Kia°.   
 When measuring the binding affinity for MgADP to the allosteric site, a 
competition experiment was performed in which the apparent Ki for PEP (Kiyapp) was 
measured at various concentrations of MgADP.  Kiyapp was then plotted as a function of 
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[MgADP] and the data were fit to the following equation to determine the Ki for 
MgADP (Kixapp): 
                                                                            (2-6) 
where KiPEP is the dissociation constant for PEP in the absence of MgADP.  All data 
analysis was performed using nonlinear least-squares fitting analysis of Kaleidagraph 
3.51 (Synergy). 
 
Site-directed Mutagenesis 
 PFK from Lactobacillus delbrueckii subspecies bulgaricus B107 was cloned into 
the plasmid pK223-3 and was kindly provided by Danone Vitapole SA, France (46).  
Mutagenesis was performed following the protocol outlined in the Quikchange Site-
Directed Mutagenesis System from Stratagene.  For all LbPFK mutants, two 
complementary oligos were designed which targeted the sequence surrounding the 
codon for the amino acid which was mutated.  The template oligos for each of the 
LbPFK variants is presented in the appropriate chapter.  The mutant plasmids were 
finally expressed in the E. coli strain MRL277, which has both the pfk1 and pfk2 genes 
deleted (90). 
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CHAPTER III 
PHOSPHATE AND SUBSTRATE-BOUND STRUCTURES OF THE NON-
ALLOSTERIC PHOSPHOFRUCTOKINASE FROM Lactobacillus delbrueckii 
SUBSPECIES bulgaricus 
 
 In most bacteria, phosphofructokinase (PFK) is allosterically regulated by two K-
type effectors, phosphoenolpyruvate (PEP) which acts as an inhibitor and MgADP 
which acts as an activator.  PFK regulation is important in the overall regulation of 
glycolysis since PFK catalyzes the first committed step where it performs a phosphoryl 
transfer from MgATP to fructose-6-phosphate (F6P) to form fructose-1,6-bisphosphate 
(FBP) and MgADP.  To better understand the regulation of bacterial PFK many studies 
have been performed on two highly regulated bacterial PFKs, those from E. coli 
(EcPFK) and Bacillus stearothermophilus (BsPFK) (91, 92).  There has also been 
extensive work done on the structures of EcPFK and BsPFK with six total structures 
submitted to the Protein Data Bank (PDB).  EcPFK and BsPFK are very similar sharing 
55% identity in amino acid sequence, and they are both homotetramers with molecular 
masses of 140 kDa (93).  Both homotetramers are formed as a dimer-of-dimers with four 
active sites and four allosteric sites.  These sites lie along respective dimer-dimer 
interfaces each containing amino acids from two adjacent monomers making it necessary 
for PFK to be a tetramer for catalytic activity and allosteric regulation (94).   
 Of the six structures in the PDB two are of EcPFK and the other four are of 
BsPFK.  The two from EcPFK are of the apoenzyme (accession code 2PFK) and the 
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product-bound enzyme with FBP and MgADP bound to the four active site and MgADP 
bound to all four allosteric sites (accession code 1PFK) (83, 95).  Comparison of these 
two structures shows that the overall secondary, tertiary and quaternary structures are 
almost identical.  The four structures from BsPFK have either phosphate bound 
(accession code 3PFK), substrate-bound (accession code 4PFK), or inhibitor-bound 
(accession code 6PFK).  A mutant BsPFK structure with substrate-bound (accession 
code 1MTO) (84, 94, 96) is also available.  The substrate-bound form has the substrate 
F6P bound to all four active sites with the product MgADP bound to both the four active 
sites and the four allosteric sites.  The inhibitor-bound structure contains the inhibitor 
analog phosphoglycolate (PG) to all four allosteric sites.  It was later determined that PG 
inhibits BsPFK in a manner similar, but not identical, to the true inhibitor PEP (79).  The 
final BsPFK structure contains the mutations W179Y, Y164W and has both F6P and 
MgADP bound to the four active sites and MgADP bound to all four allosteric sites (96). 
This structure is very similar to the substrate-bound form of wild-type BsPFK.  By 
comparing the substrate-bound form to the inhibitor-bound form, Schirmer and Evans 
proposed a model for the allosteric control of BsPFK (84).  This model conforms to the 
two-state model proposed by Monod, Wyman and Changeax (MWC) in which the 
enzyme is found in one of two states, the active, relaxed R-state or the inhibited, tense T-
state (70, 84).  The allosteric behavior of EcPFK was thought to conform to the MWC 
model as well (91). 
 The seventh PFK structure belongs to PFK from Lactobacillus delbrueckii 
subspecies bulgaricus (LbPFK, accession code 1ZXX) (82).  LbPFK, unlike that of 
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EcPFK and BsPFK, has very weak binding affinity for the allosteric ligands PEP and 
MgADP (approximately 27 mM) and is therefore considered a non-allosteric form of 
PFK (82, 97).  LbPFK is similar to EcPFK and BsPFK in amino acid sequence having 
57% identity to BsPFK and 47% identity to EcPFK.  The structure of LbPFK contains 
sulfate bound to all four active sites and all four allosteric sites.  Upon comparison to the 
substrate-bound forms of BsPFK and EcPFK, the overall structure of LbPFK is similar 
with the only major differences found within the allosteric binding site (82).   
 Here, two new crystal structures of LbPFK are presented.  The first structure 
contains phosphate bound at the four active sites along with the four allosteric sites and 
was solved to 1.83 Å resolution.  The second has the substrate F6P bound within the four 
active sites along with phosphate bound to the four active sites and four allosteric sites 
and was solved to 2.2 Å resolution.  In each of the structures an additional phosphate is 
bound to the surface of the enzyme and this is thought to be an artifact of the 
crystallization.  There are also ions bound to each, with a chloride ion bound within the 
four active sites of the phosphate-bound structure and a magnesium anion bound within 
the four active sites of the substrate-bound structure.  These are most likely due to the 
fact that the storage conditions for LbPFK contain MgCl2.  These are the first crystal 
structures of LbPFK with substrate bound and phosphate bound, and they allow for 
further comparisons to be made between LbPFK and the more allosterically responsive 
enzymes EcPFK and BsPFK.       
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Materials and Methods 
Materials 
 The crystallization reagents were purchased from Hampton Research (Aliso 
Viejo, CA). 
 
Crystallization and Data Collection for LbPFK Structures 
 LbPFK was crystallized using the hanging drop vapor diffusion method (98) at 
16 °C.  For phosphate-bound LbPFK, crystallization was achieved in a 5 µL drop with 
2µL solvent (0.1 M Tris-HCl pH 8.5, 2.0 M ammonium phosphate monobasic) and 3 µL 
protein (stock concentration of LbPFK was 7.6 mg/mL in 50mM Tris-HCl, pH 7.5, 1mM 
EDTA and 10mM MgCl2).  For substrate-bound LbPFK, crystallization was achieved in 
a 5 µl drop with 2µl solvent (0.1 M Tris-HCl pH 8.5, 2.0 M ammonium phosphate 
monobasic) and 3 µl protein (stock concentration of LbPFK was 9.6 mg/mL in 50mM 
Tris-HCl, pH 7.5, 1mM EDTA, 10mM MgCl2 and 2.5mM F6P).  Within 24 hours, 
diamond shaped crystal for both LbPFK proteins were formed.  For data collection, 
crystals were cryoprotected by brief soaking in 30% ethylene-glycol and then flash-
frozen in a liquid N2 stream at 100 K. Diffraction data for the LbPFK-phosphate bound 
crystal was collected on APS beamLine 23-ID using the MAR CCD detector 
(MarMosaic from Marresearch – Charged Coupled Device) (Rayonix LLC, Evanston, 
IL). Diffraction data for Lb-PFK-F6P were collected to resolution 2.2 Å on a Raxis 
IV++ detector in lab (Rigaku). The HKL2000 program package (HKL Research, Inc., 
Charlottesville, VA) (99) was used for integration and scaling. Crystals belong to the 
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space group P6222 with unit cell parameters with one molecule in the asymmetric unit.  
Data collection details are summarized in Table 3-1. 
 
Structure Determination and Refinement for LbPFK Structures 
The molecular replacement program PHASER (University of Cambridge, UK) 
(100) was used to solve the structures of LbPFK using the sulfate-bound crystal structure 
of LbPFK (1ZXX) (82) with waters and ions removed as a model.  Rigid body 
refinement followed by simulated annealing refinement at 5000 K was carried out using 
Phenix (Python-based Hierarchical Environment for Integrated Xtallography, Berkeley, 
CA) (101).  Subsequently, refinement was carried out in alternating cycles of manual 
model building in COOT (Crystallographic Object-Orientated Toolkit, Oxford, UK) 
(102) followed by refinement as implemented in Phenix until R-factors converged.  
Water molecules were added in the difference electron density maps at positions 
corresponding to peaks (>3.0σ) and with appropriate hydrogen bonding geometry. The 
stereochemical quality of the final model for the LbPFK proteins was verified by 
Molprobity (Duke University, Durham, NC) (103). 
 
Results 
 Structural Characteristics of Phosphate-bound LbPFK 
 The phosphate-bound LbPFK crystals belong to the space group P6222 with unit 
cell parameters a=135.0 Å, b=135.0 Å and c=77.7 Å and a hexagonal shape.  The 
asymmetric unit contains a single monomer and the final structure was refined to R-
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factor/R-free values of 22.29%/26.91% and has a 1.83 Å resolution.  This structure has 
the highest resolution of LbPFK structures solved to date.   Each monomer contains 319 
residues, 214 water molecules, 12 phosphates and four magnesium ions.  The details of 
the final refinement parameters are shown in Table 3-1.   
Figure 3-1A shows the overall structure of the phosphate-bound LbPFK from 
two alternate views.  There are three phosphate molecules bound per subunit, one in the 
active site, one in the allosteric site and one on the surface of the enzyme.  The one in the 
active site forms potential hydrogen bonds with R252, R243, H249 and a H20 molecule.  
When compared to the substrate-bound structure of BsPFK this phosphate appears to be 
positioned in the same area as the phosphate of F6P.  The phosphate in the allosteric site 
could potentially interact with several residues including R21, R25 and R154 along with 
H215, which are all conserved between LbPFK, EcPFK and BsPFK.  The surface 
phosphate is positioned to interact with R194 and K312.  Since these residues are not 
involved in binding of either the substrates or effectors, the binding of this phosphate is 
most likely due to the crystallization conditions. 
 
Characteristics of Substrate-bound LbPFK 
The substrate-bound LbPFK crystals belong to the space group P6222 with unit 
cell parameters a=134.5 Å, b=134.5 Å and c=77.7 Å and a hexagonal shape.  The 
asymmetric unit containing a single monomer and the final structure was refined to R-
factor/R-free values of 19.86%/23.25% and has a 2.20 Å resolution.  Each monomer 
contains 319 residues, 138 H2O molecules, 12 phosphates, four F6P molecules and 
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Table 3-1.  Data collection and refinement statistics for LbPFK strucuresa 
Data set phosphate-bound 
LbPFK 
Substrate-bound 
LbPFK 
Unit cell (Å) a=135.0 a=134.5 
 b=135.0 b=134.5 
 c=77.7 c=77.7 
Space group P6222 P6222 
Monomers per asymmetric unit 1  1 
Resolution (Å) 68-1.83 47-2.2 
Redundancy 13.54(2.01) 21.3(21.1) 
Observations 34,307 21,557 
Observations (Test set) 1,432 1,106 
Completeness (%) 92.7(40.1) 100(100) 
Rmerge 0.089(0.549) 0.069(0.450) 
I/Iσ 12.1(1.4) 74.3(11.6) 
Refinement   
Resolution (Å) 68-1.83 47-2.2 
Rcryst (%) 22.29 19.86 
Rfree (%) 26.91 23.25 
Number of protein atoms/number of 
waters 
2380/214 2372/138 
Number of ligands (including ions) 19 32 
Average B factor (Å
2
) 36.8 54.3 
rmsd bond length (Å) 0.004 0.007 
rmsd bond angles (°) 0.566 0.964 
Ramachandran statistics   
      most favored 97.79% 98.11% 
      Allowed 2.21% 1.89% 
a For details of the crystallization and structure determination, see text.  Values in 
parentheses are for high resolution shells.  Rmerge = ΣhΣi|Ihi - <Ihi>|\ΣhΣiIhi where Ihi is the 
ith observation of the reflection h, where <Ih> is the mean intensity of reflection h.  Rcryst 
= Σh|Fo| - |Fc|/|Fo|. Rfree was calculated with a fraction (5%) of randomly selected 
reflections excluded from refinement.  rmsd, root-mean-square deviations from ideal 
geometry. 
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four chloride ions.  The details of the final refinement parameters are shown in Table 3-
1.  
Figure 3-1B shows two views of the overall structure of the substrate-bound 
structure of LbPFK.  This structure contains F6P in all four active sites along with a 
phosphate as well as a phosphate bound to the allosteric site and on the surface of the 
protein.  The location of the phosphate in the allosteric site and on the surface of the 
enzyme is similar to that seen in the phosphate-bound LbPFK structure.  The main 
difference between the structures is the position of the phosphate within the active site.  
The F6P is bound in a similar way as in the substrate-bound BsPFK structure (Figure 3-
2).  It interacts with R127, R171, R243 and R252 as well as G170, E222 and H249.  
Upon the addition of F6P to the active site, the free phosphate moves to a new position 
where is now interacts with R162 but still keeps its interaction with R252.  When 
compared to the substrate-bound BsPFK structure, the free phosphate is positioned 
between where F6P and MgADP would potentially bind.   This could mean that the free 
phosphate is bound close to where the γ-phosphate of MgATP would be bound and then 
transferred to F6P to form FBP during catalysis. 
 
Active Site Comparison 
 Figure 3-2 shows a close-up of the active site for BsPFK (3-2A) and LbPFK (3-
2B).  In both cases a comparison was made between the phosphate-bound structures and 
the substrate-bound structures.  For BsPFK, it appears that the only major difference 
between the two structures is the position of R171.  This R moves towards the F6P  
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Figure 3-1.  Phosphate-bound and substrate-bound LbPFK structures. Subunit A colored 
yellow, subunit B colored pink, subunit C colored blue and subunit D colored green, 
phosphates colored red, F6P colored purple and ions colored black.  View showing the 
substrate binding interface between subunit A and B on the right and alternate view with 
a 90 ° rotation along the horizontal axis on the left for (A) Phosphate-bound structure 
with calcium ion bound and (B) Substrate-bound structure with magnesium ion bound.    
 
 
 
 
A 
B 
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molecule putting the NH1 3.0 Å from the OH of the F6P molecule.  In the absence of 
F6P, this arginine is facing out of the active site and only interacts with the solvent 
surrounding the enzyme.  There is also a minor shift in E241, which causes a break in 
the potential hydrogen bond with R162 (which is present in the phosphate structure but 
absent when F6P is bound).  However, this change does not affect the interaction 
between R162 and either PO4 or F6P, as these hydrogen bonds remain intact.  
  As with BsPFK, the only major difference in the location of the residues within 
the active site is the movement of R171.  Again, it moves towards the bound F6P to form 
a potential hydrogen bond with the OH of the ring.  All the other residues are not greatly 
displaced.  There are however differences when comparing the actual amino acids 
between the active sites of BsPFK and LbPFK.  In BsPFK, as mentioned before, E241 
interacts with R162 in the phosphate-bound structure but this interaction is absent in 
LbPFK since there is now a D at 241.  The shortening of the chain doesn’t allow for the 
hydrogen bond with R162.   R162 instead interacts with the free phosphate when F6P is 
bound and does not form any interaction in the presence of only phosphate. 
 
Allosteric Site Comparison 
 The allosteric site was the area that contains the largest differences in comparing 
the non-allosteric LbPFK to the allosteric BsPFK and EcPFK.  To keep things simple, 
only a comparison between LbPFK and BsPFK is presented.  When comparing the 
allosteric sites between the substrate-bound and the phosphate-bound structures of both 
BsPFK and LbPFK, only a few differences appear within the allosteric site of BsPFK 
 45 
 
 
Figure 3-2.  Active site comparison between phosphate-bound and substrate-bound 
forms of (A) BsPFK and (B) LbPFK.  Phosphate-bound structures in blue with substrate-
bound structures in green with F6P highlighted in purple and free phosphates highlighted 
in pink, light pink for phosphate-bound structure and dark pink for phosphate bound in 
substrate-bound structure LbPFK.  Amino acid residues are labeled with three-letter 
abbreviations and numbers.  Amino acid residues 161, 162, 241 and 243 are from one 
monomer with 127, 170, 171, 222, 249 and 252 belonging to the monomer across the 
active site interface.   
 
 
 
 
 
 
A 
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(Figure 3-3A) and no major changes appear in LbPFK (Figure 3-2A).  In the substrate-
bound structure of BsPFK, MgADP is bound to the allosteric site.  Figure 3-3A shows a 
comparison between the allosteric sites of the substrate-bound and phosphate-bound 
BsPFK.  Of the many residues which come in contact with the ligands, the region 
containing residues 213-215 appears to change positions the most.  In both LbPFK and 
BsPFK, there is a K at position 213 and an H at position 215.  However, residue 214 is 
quite different, with BsPFK having a K and LbPFK having a D (Figure 3-3C). 
In the phosphate-bound structure, K214 forms a hydrogen bond with the 
carbonyl oxygen of H206 but when MgADP binds to the allosteric site, K214 moves 
inward towards MgADP and forms a new hydrogen bond with the carbonyl oxygen of 
G212.  The movement of K214 occurs at the same time as the movement of K213 and 
H215 which also move closer to MgADP causing K213 to hydrogen bond with both 
MgADP and H215.  These movements appear to be important for the positioning of 
MgADP in the allosteric binding site. 
 D214 in LbPFK interacts with several other residues within the allosteric binding 
site. D214 forms hydrogen bonds with H59, two water molecules, H215 and Y69 which 
is located in the adjacent monomer.  The hydrogen bond between 214 and 59 would not 
occur in BsPFK since K214 and D59 are not in close enough contact in either the 
phosphate-bound structure (16 Å) or the substrate-bound structure (11 Å).  As can be 
seen in figure 3-3C, along with residues 214 and 59 there are other differences within the 
allosteric binding site including residue 55.  In BsPFK there is a glycine at position 55 
while LbPFK has a glutamate.  These differences could help explain the weak binding 
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Figure 3-3.  Allosteric site comparison between various BsPFK and LbPFK structures.  
(A) phosphate-bound BsPFK (yellow) vs. substrate-bound BsPFK (red) with MgADP 
(blue) and PO4 (pink). (B) Phosphate-bound (yellow) LbPFK vs. substrate-bound (red) 
LbPFK with PO4 (pink) and PO4 bound with F6P (blue). (C) Phosphate-bound BsPFK 
(black) vs. phosphate-bound LbPFK (cyan) with bound PO4 highlighted.   Individual 
residues which form potential interactions with various ligands labeled. 
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affinity for effector ligands seen in LbPFK. 
 
B-factor Comparison between LbPFK Structures 
 The B-factor, or temperature factor, in crystal structures is thought to be a 
measurement of how much an atom oscillates or vibrates around the position specified 
by the model.  Through the refinement process the B-factor is computed for each of the 
main-chain and side-chain atoms and from these values it is possible to gain some 
insight into the dynamics of the protein.  A small value for the B-factor indicates less 
movement compared to a high value which would indicate more movement (104).  
Figure 3-4 shows the B-factor comparison between the phosphate-bound and substrate-
bound structures of LbPFK.   From the comparison of the tetramers it is clear that the 
over-all structure becomes much more rigid upon binding of F6P to the four active sites 
(Figure 3-4A).  Upon closer inspection of the dimer-dimer interfaces, it is clear that both 
interfaces increase in their rigidity especially along with active site interface (Figure 3-
4B).  The allosteric site interface also becomes more rigid but is still more flexible 
compared to the active site interface for both LbPFK structures (Figure 3-4C).  Some of 
these differences could be due to the differences in the resolution of the two structures 
but overall suggest a more rigid structure when the substrate F6P is bound. 
 Since the B-factor can also help in determining the validity of the model in the 
final structure, care must be taken when comparing B-factors between two structures 
with different resolutions (104).  The phosphate-bound and sulfate-bound structures are 
different in resolution, 1.83 Å and 2.2 Å respectively, which indicate that both are high  
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Figure 3-4.  B-factor comparison of LbPFK structures with substrate-bound (left) and 
phosphate-bound (right).  (A) Comparison of LbPFK tetramers.  (B) Comparison of 
LbPFK dimers focusing along active site interface.  (C) Comparison of LbPFK dimers 
focusing along allosteric site interface.  Bound ligands are depicted as space filled 
molecules with F6P in purple and P04 in pink.     
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resolution structures.  Therefore, the comparison of B-factors between these two 
structures will likely give insight into the differences in the overall rigidity of the 
structures.   
 
Discussion  
For many years the regulation of prokaryotic PFKs has been studied using crystal 
structures (82-85, 94, 95).  From these studies several models have been proposed 
concerning the allosteric regulation of BsPFK and EcPFK and the possible reason for the 
weak binding for the allosteric ligands seen in LbPFK.  In BsPFK, it was proposed that 
the transition between the active, R-state and the inhibited, T-state was due to a 
quaternary shift along the active site interface accompanied by binding of PG (84).  This 
quaternary shift was also accompanied by several secondary-structural changes one of 
which involved residues within the allosteric binding site.  A more recent study had 
shown that this quaternary shift is actually move important for the binding of the 
inhibitor, PEP, than the actual allosteric inhibition (85).  In that study, several new 
crystal structures were determined including the apoenzyme of BsPFK and the PEP-
bound D12A BsPFK.  Comparative analysis of these structures with the other structures 
of BsPFK allowed for further insight into the allosteric mechanism of BsPFK. 
 When comparing the apoenzyme of BsPFK to the substrate-bound and the PG-
bound BsPFK structures determined that only the PG-bound structure had undergone the 
quaternary shift and that significant differences in the B-factors for the amino-acid side-
chains were evident.  B-factor analysis has been used in numerous crystal structure 
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comparisons to show what happens upon ligand binding as well as to indicate 
differences in protein stability between the same proteins from thermophilic and 
mesophilic organisms (105, 106).  In the comparison of BsPFK structures, it was found 
that the substrate-bound structure was the most flexible and the PG-bound was the most 
rigid, with the apoenzyme being somewhere in between.  Also, the active site interface 
was determined to be more flexible than the allosteric site interface which would allow 
for the quaternary shift to occur along the active site interface.  The only exception was 
the region containing residues 156-162 which is more rigid in the substrate-bound 
structure compared to the other two structures.  This region has been implicated to be 
involved in the quaternary shift since the helix containing 156-162 changes secondary 
structure upon binding of the inhibitor PEP as well as several residues being involved in 
important hydrogen bonds across the active site interface (85).  This shows how the 
comparison of B-factors can shed some light on the role of certain regions within the 
protein in the binding of ligands.   
 When comparing the B-factors for each of the two LbPFK structures, it is clear 
that the substrate-bound structure is much more rigid overall than the phosphate-bound 
structure.  In each structure the interior of the enzyme is more rigid than the exterior with 
several of the solvent exposed helices being the most flexible.  By looking at the PFK 
dimers, each split along the opposite dimer-dimer interface, it is also evident that the 
active site interface is more rigid than the allosteric site interface.  Increased flexibility 
along the active site interface is opposite of what was seen in BsPFK and could be an 
explanation for the weak binding affinity for the effector ligands in LbPFK.  Since both 
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LbPFK structures were crystallized under similar conditions and have the same crystal 
contacts, the differences in the B-factors for the main-chain are most likely due to 
binding of the various ligands.  Therefore, since the only difference in the ligand binding 
between the two is the presence of F6P in the active site and the movement of the 
phosphate within the active site, it may be that the binding of F6P is causing the over-all 
structure to become more rigid.  This could potentially lock the enzyme in a catalytically 
favorable structure where only the two substrates F6P and MgATP could bind and the 
reaction take place.   
 This lock in structure along with the non-conservation of the allosteric site 
between LbPFK and the allosteric PFKs could explain its weak binding for both 
allosteric ligands.  Having a very rigid active site interface might inhibit the quaternary 
shift from occurring and therefore make it even harder for the allosteric ligands to bind.  
Therefore, it is necessary to look at both the active site interface as well as the allosteric 
binding site when attempting to make mutations which would enhance binding for either 
PEP or MgADP.  It would also be of interest to solve the crystal structures for any 
mutants which enhance binding for the allosteric ligands and compare the B-factors for 
those structures to the ones presented here to test these predictions. 
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CHAPTER IV 
THE EFFECT OF CONSERVED RESIDUES ON THE BINDING OF AN 
ALLOSTERIC LIGAND FROM A DISTANCE 
 
 Phosphofructokinase (PFK) is an allosterically regulated, glycolytic enzyme 
which catalyzes the phosphoryl transfer from MgATP to fructose-6-phosphate (F6P) to 
form MgADP and fructose-1,6-bisphosphate.  In bacteria, PFK is usually allosterically 
regulated by two ligands, phospho(enol)pyruvate (PEP) which acts as an inhibitor and 
MgADP which acts as an activator.  Both ligands bind to the same allosteric site, but 
exert opposite effects.  PFK is structurally a homotetramer with four active sites and four 
allosteric sites.  It is assembled as a dimer of dimers, and the binding sites lie along 
respective dimer-dimer interfaces.  The structures of both PFK from E. coli (EcPFK) and 
Bacillus stearothermophilus (BsPFK) have been determined with various ligands bound 
(83, 84, 94, 95).  From these structures, there has been a model proposed to explain the 
structural basis for allosteric regulation (84).  In this model, the substrate-bound 
structure of BsPFK with MgADP and F6P bound to the active site as well as MgADP 
bound to the allosteric site is contrasted to the inhibitor-bound structure of BsPFK with 
phosphoglycolate (PG) bound to the allosteric site.  It was proposed that the inhibition 
exerted by PG was accompanied by a 7° shift along the active site interface.  Along with 
the large quaternary change, several changes in secondary structure occur including the 
movement of a loop located in the allosteric site.  This model has been used extensively 
in the literature to explain the allosteric inhibition of PFK.   
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In the model proposed by Schirmer and Evans, one of the secondary changes 
which occurs upon the 7° shift, also referred to as the quaternary shift, involves an α-
helix and loop containing the amino acid residues 155-162 and the surrounding residues.  
Several of these residues are involved in hydrogen bonds across the active site interface 
and upon the quaternary shift, this hydrogen bonding pattern is changed.  The residues 
which are involved in these hydrogen bonds are T156, S159 and H160.  All of these 
form a hydrogen bond with D12 across the active site interface.  D12 also hydrogen 
bonds within the same subunit with R252, which in turn interacts with the substrate F6P 
in the active site.  Upon binding of PG, this hydrogen bonding pattern is interrupted and 
a new hydrogen bond is formed between D12 and T158 as well as a salt bridge between 
R72 and E241.  These changes in hydrogen bonds are proposed to be involved in the 
inhibition of PFK by the inhibitor PEP even though the allosteric binding site is 15 Å 
away. 
 Several of the residues involved in the quaternary shift are 100% conserved when 
comparing 150 bacterial ATP-dependent PFK sequences.  These include D12, T156 and 
R252.  S159 and H160 are also highly conserved.  T156, S159 and H160 were all 
mutated in EcPFK to the corresponding residues in BsPFK or rabbit muscle PFK (both 
the C-terminal and N-terminal regions) and exhibited various effects on both substrate 
and effector binding affinities (107).  In the case of H160, when mutated to an N, there 
was a decrease in the binding affinity for F6P as well as for PEP, which as mentioned 
previously is located far away from the allosteric binding site.  T156, when changed to 
either a G or S, exhibited weaker binding affinity for F6P and surprisingly activation in 
 55 
the case of PEP (107).  Activation by T156E/S is similar to that seen when E187, which 
is located within the allosteric site, is mutated to an A (108).  The activation by PEP was 
proposed by Kundrot and Evans to involve the residues within the region between T156 
and the allosteric binding site (107).  Finally, when S159 was mutated to an N, the 
effects were similar for the binding of F6P as seen with H160N and T156G/S as well as 
the effect on PEP binding being weaker as with H160N.  The effects were explained due 
to the structural changes seen between the shift from substrate-bound to inhibitor-bound 
in BsPFK, but shows the need for a model in which intermediate states are allowed. 
 Even though all of these residues form hydrogen bonds with D12, it wasn’t until 
more recently that the effect upon mutating D12 would have on the properties of 
bacterial PFK was studied.  D12A was first introduced in BsPFK in combination with 
R252A and this showed a weakening in the binding for the substrate F6P as well as 
enhanced binding for PEP (73).  A more extensive study of D12A in BsPFK found that 
this mutation weakened F6P binding 50-fold, increased the binding affinity for PEP by 
100-fold but had little to no effect on the extent of inhibition seen with PEP when 
compared to wild-type BsPFK (85).  A structure of D12A BsPFK was also solved to 2.0 
Å resolution with the inhibitor PEP bound to the allosteric site, which is the first time a 
structure of PFK has been solved with the physiological inhibitor bound.  This structure 
is quite similar to that of the PG-bound BsPFK structure solved by Evans and colleagues 
and exhibits the same structural changes seen upon the quaternary shift.  T156A was also 
introduced in BsPFK and has similar properties as seen in D12A, but not to the same 
degree.  A PEP bound structure of T156A was also solved in BsPFK and this structure, 
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as with D12A, shows the characteristics of the quaternary shift (85).  These results 
suggest that the quaternary shift is most likely involved in the binding of PEP but not in 
its ability to inhibit PFK. 
 Unlike EcPFK and BsPFK, PFK from the lactic acid bacteria Lactobacillus 
delbrueckii subspecies bulgaricus (LbPFK) has weak binding for both allosteric ligands, 
and both ligands inhibit at high concentrations (82).  The structure of LbPFK was 
recently solved to 1.83 Å resolution with phosphate bound to all eight sites and 
comparison between this structure and those of BsPFK and EcPFK show high over-all 
conservation in structure (see Chapter III). The hydrogen bonding pattern between D12 
and the residues across the active site interface, T156 and H160 is also present in the 
LbPFK structure.  It is unclear if there is a potential hydrogen bond between D12 and 
S159 in LbPFK.  D12 also interacts with R252 within the same subunit, as seen in 
BsPFK.   
To investigate the role of this hydrogen bonding network in LbPFK, D12, T156 
and H160 were mutated to A.  H161, which is an E in BsPFK and a Q in EcPFK, was 
also mutated to A.  H161 could potentially take the place of H160 in the H160A variant, 
therefore the single H161A variant was created as well as the combination variant 
H160A/H161A.  All of these mutants, with the exception of H161A, showed diminished 
binding for the substrate F6P.  D12A also exhibited a 7-fold enhancement in MgATP 
binding compared to LbPFK.  D12A was the only mutant to show enhancement in PEP 
binding and therefore was analyzed for MgADP binding.  MgADP binds 9-fold tighter 
to D12A compared to wild-type.  MgADP continues to act as an inhibitor even though 
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MgADP acts as an activator in other allosteric PFKs such as EcPFK.  D12A LbPFK was 
crystallized and solved to 2.3 Å resolution.  Sulfate was bound to all eight sites and 
when compared to the sulfate bound wild-type LbPFK structure, no major structural 
changes are observed.   The change in PEP binding and structure is small compared to 
that seen in BsPFK, and may be due to the other differences within the enzymes such as 
the lack in conservation at the allosteric site. 
 
Methods 
Site-directed Mutagenesis 
 The strategy employed for site-directed mutagenesis is similar to that discussed 
in Chapter II.  Below are the template strands for the oligonucleotides used in 
combination with the complementary strand in the creation of D12A, T156A, H160A, 
H161A and H160A/H161A.  For the creation of H160A/H161A, an additional 
oligonucleotide was needed to introduce H161A into the plasmid pK223-3 that already 
contained the mutated H160A LbPFK gene.  Figure 4-1 shows the oligonucleotides used 
with the codon that was changed in the mutagenesis reaction underlined. 
 
Protein Purification for D12A 
 D12A LbPFK was purified following the protocol for LbPFK in Chapter II with 
the following exceptions.  The buffer used throughout the purification contained 1mM 
F6P and the cell lysate was applied to a 100 mL pre-equilibrated Mimetic-Blue A 
column and washed at 4°C.  Also, the protein eluted from the column during the wash  
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D12A:  ACT GGC GGT GCC GCC CCT GGT ATG 
T156A: C GAC AAG ATC CGT GAC ACT GCT TTC TAG CCA CC   
H160A:  AC ACT GCT TCT AGC GCC CAC CGC GTC TTC ATT G 
H161A:  C ACT GCT TCT AGC CAC GCC CGC GTC TTC ATT GTC  
H161A for H160A:  CT GCT TCT AGC GCC GCC CGC GTC TTC ATT G 
Figure 4-1.  Template strands used for site-directed mutagenesis to create the active site 
mutations in LbPFK.   For each LbPFK variant (bolded), the DNA sequence for the 
template strand is shown and was used along with the complementary strand to introduce 
the change in the DNA sequence.   
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and the fractions containing PFK activity were pooled and 5mM MgCl2 added to the 
sample.   
 
Protein Purification for H160A, H161A and H160A/H161A 
 H160A LbPFK was purified following the protocol for LbPFK in Chapter II with 
the exceptions of having 1mM F6P in buffers throughout the purification and a 0-1M 
NaCl gradient applied to the Mimetic BlueA column.  H160A LbPFK was stored at 4°C 
in Buffer A (50mM Tris-HCl pH 7.5, 0.1 mM EDTA), 1mM F6P and 10% glycerol. 
 H161A LbPFK was purified as described for LbPFK in Chapter II with the 
exceptions being the presence of 1mM F6P in the buffers throughout the purification, 
and after eluting from the Mimetic-Blue A column with a 0-2M NaCl gradient, fractions 
containing PFK were pooled and dialyzed into Buffer A + 1mM F6P.  Following dialysis 
the sample was applied to an anion-exchange MonoQ column, washed with Buffer A + 
1mM F6P and eluted with a 0-1M NaCl gradient in Buffer A + 1mM F6P.  The fractions 
containing PFK activity were pooled and dialyzed into Buffer B (Buffer A + 5mM 
MgCl2) + 1mM F6P. 
 H160A/H161A was purified with the following exceptions.  After eluting from 
the Mimetic- Blue A column, the fractions containing PFK were pooled and dialyzed 
into Buffer A.  The sample was then applied to two anion-exchange MonQ columns, the 
first at pH 7.5 followed by a second at pH 6.0.  In both cases the column was eluted with 
a 0-0.7M NaCl gradient in Buffer A, the fractions containing PFK pooled and then 
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dialyzed into the appropriate buffer.  The final sample was dialyzed into Buffer B and 
stored at 4°C. 
 
Protein Purification for T156A 
 6L of LB containing ampicillin were inoculated with an overnight culture of cells 
containing the plasmid pK223-3 that contained the T156A LbPFK gene (2 mL of the 
overnight were used to inoculate each 1.5L sample).  Samples were grown at 37°C to an 
OD600=1.4, cooled to 15°C and allowed to grow at 15°C for 24 hours.  Cells were 
harvested and the pellet stored at -80°C.  The purification was performed following the 
protocol for LbPFK in Chapter II with the following exceptions.  All buffers throughout 
the purification contained 1mM F6P and the majority of the PFK eluted off the Mimetic-
Blue A column during the wash step.  All fractions containing PFK activity were pooled 
and concentrated to a final volume of 20 mL with polyethylene glycol  (PEG).  50% 
ammonium sulfate was then added to the sample and the sample incubated for 30 
minutes on ice with constant stirring.  The sample was dialyzed into Buffer A to remove 
ammonium sulfate and concentrated to 4 mL with PEG.  The sample was then applied to 
a S200 gel-filtration column at 4°C at a rate of 0.2 mL/min and 1 mL fractions collected.  
All fractions containing PFK activity were pooled, dialyzed into Buffer B and stored at 
4°C.   
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Crystallization and Data Collection for D12A LbPFK 
D12A LbPFK was crystallized using the hanging drop vapor diffusion method 
(98) at 16 °C.  Crystallization was achieved in a 6 µL drop with 2µL solvent (0.1 M 
sodium acetate trihydrate pH 4.6, 2.0 M ammonium sulfate) and 4 µL protein (stock 
concentration of LbPFK was 13.3 mg/mL in 50mM Tris-HCl, pH 7.5, 1mM EDTA and 
1mM F6P).  Within 24 hours, diamond shaped crystals were formed.  For data 
collection, crystals were cryoprotected by brief soaking in 30% ethylene-glycol and then 
flash-frozen in a liquid N2 stream at 100 K.  Diffration data were collected to a 
resolution 2.3 Å on a home-source Raxis IV++ detector (Rigaku). The HKL2000 
program package (HKL Research, Inc., Charlottesville, VA) (99) was used for 
integration and scaling. Crystals belong to the space group P6222 with unit cell 
parameters containing one molecule in the asymmetric unit.  Data collection details are 
summarized in Table 4-1. 
 
Structural Determination and Refinement of D12A LbPFK 
The molecular replacement program PHASER (University of Cambridge, UK) 
(100) was used to solve the structure of D12A LbPFK using the sulfate-bound crystal 
structure of LbPFK (1ZXX) (82) with waters and ions removed as a model.  Rigid body 
refinement followed by stimulated annealing refinement at 5000 K was carried out using 
Phenix (Python-based Hierarchical Environmnet for Integrated Xtallography, Berkeley, 
CA) (101).  Subsequently, refinement was carried out in alternating cycles of manual 
model building in COOT (Crystallographic Object-Orientated Toolkit, Oxford, UK)  
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Table 4-1.  Data collection and refinement statistics for D12A LbPFK structurea 
 
Data set D12A LbPFK 
Unit cell (Å) a=135.4 
 b=135.4 
 c=77.7 
Space group P6222 
Monomers per asymmetric unit 1  
Resolution (Å) 50-2.3 
Redundancy 30.2(29.8) 
Observations 20,143 
Observations (Test set) 977 
Completeness (%) 99.7(96.9) 
Rmerge 0.082(0.576) 
I/Iσ 83.92(9.03) 
Refinement  
Resolution (Å) 50-2.3 
Rcryst (%) 17.48 
Rfree (%) 21.41 
Number of protein atoms/number of 
waters 
2388/157 
Number of ligands (including ions) 15 
rmsd bond length (Å) 0.007 
rmsd bond angles (°) 0.927 
Ramachandran statistics  
      most favored 98.42% 
      Allowed 1.58% 
 
a For details of the crystallization and structure determination, see text.  Values in 
parentheses are for high resolution shells.  Rmerge = ΣhΣi|Ihi - <Ihi>|\ΣhΣiIhi where Ihi is the 
ith observation of the reflection h, where <Ih> is the mean intensity of reflection h.  Rcryst 
= Σh|Fo| - |Fc|/|Fo|. Rfree was calculated with a fraction (5%) of randomly selected 
reflections excluded from refinement.  rmsd, root-mean-square deviations from ideal 
geometry. 
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(102) followed by refinement as implemented in Phenix until R-factors converged.  
Water molecules were added in the difference electron density maps at positions 
corresponding to peaks (>3.0σ) and with appropriate hydrogen bonding geometry. The  
stereochemical quality of the final model for the LbPFK proteins was verified by 
Molprobity (Duke University, Durham, NC) (103). 
 
Results 
Steady-state Kinetics of D12A LbPFK  
Weak binding of the allosteric ligands, PEP and MgADP, to the allosteric site of 
LbPFK has been previously thought to be due to the lack of conservation of amino acids 
within the allosteric binding site (82).  The role of these non-conserved residues in the 
binding of both PEP and MgADP is discussed in Chapter 5 of this dissertation.  Another 
region which has been identified to have a role in PEP binding in BsPFK is the area 
surrounding the 100% conserved D12 (73, 85).  D12 is located along the dimer-dimer 
interface that contains the four active sites and is located approximately 6 Å from the 
active site.  D12 interacts with R252 that in turn interacts with the substrate F6P.  Upon 
changing D12 to an A (D12A), the binding affinity for PEP in BsPFK increases 100-fold 
compared to wild-type and a nearly 7° quaternary shift along the active site interface is 
induced (85). Since D12A enhances the affinity of BsPFK for PEP, this mutation was 
introduced into LbPFK. 
The steady-state kinetics parameters were measured for D12A LbPFK and 
compared to the wild-type enzyme.  Figure 4-2 shows titration curves for F6P and 
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MgATP comparing D12A to LbPFK.  Due to an 8-fold decrease in the overall specific 
activity upon introducing D12A, the rates shown in Figure 4-2 are normalized.  It is 
evident from the shifting of the titration curve right that the binding affinity for F6P is 
diminished (Figure 4-2A) while the titration curve for MgATP (Figure 4-2B) is shifted 
to the left, indicating an enhancement in binding for D12A compared to wild-type.  Both 
changes are approximately 7-fold (Table 4-2) and could be explained by the proximity of 
D12 to the active site.  
D12A not only effects binding of both substrates to the active site but also the 
binding affinity for the allosteric ligands PEP and MgADP to the allosteric site.  Since 
PEP and MgADP are K-type allosteric effectors, i.e. binding of these ligands to the 
allosteric site affects the binding of the substrate F6P to the active site, the binding 
affinity for F6P was measured at various concentrations of either PEP or MgADP.  
Figure 4-3 shows the effect for both PEP and MgADP on F6P binding for D12A LbPFK.   
Binding for both PEP and MgADP were enhanced, 9-fold and 11-fold respectively, 
compared to WT LbPFK as well as allosteric inhibition being exhibited in both cases 
(Table 4-2).  Since saturation of either allosteric ligand could not be reached in these 
experiments, the allosteric response could not be quantitated, i.e. Qay and Qax could not 
be determined.  Qay and Qax are the coupling constants which describe both the nature of 
the allosteric effector as well as the magnitude of the allosteric effect (88).  The 
inhibition of F6P binding exhibited by MgADP is most likely due to an allosteric effect 
and not to product inhibition since all the experiments were performed in the saturating 
presence of MgATP.  MgATP is also present in equal molar concentrations with  
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Figure 4-2.  Substrate titration curves for wild-type LbPFK and D12A LbPFK at 25°C, 
pH 8.0.  (A) F6P titration curves for LbPFK (pink) and D12A LbPFK (blue).  The 
experiment was performed with [MgATP] = 15 mM for LbPFK and 3mM for D12A 
LbPFK.  (B)  MgATP titration curves for LbPFK (pink) and D12A LbPFK (blue).  
Experiment was performed with [F6P] = 3mM for LbPFK and 5mM for D12A LbPFK.  
In both experiments, the specific activity was normalized for each PFK to the 
appropriate Vmax, 250 U/mg for LbPFK and 28 U/mg for D12A LbPFK.   
 
 
 
 
 
 
 66 
 
Figure 4-3.  Binding and allosteric response of PEP and MgADP for wild-type and 
D12A LbPFK at 25°C, pH 8.0.  The K1/2 for F6P was measured at various concentrations 
of (A) PEP or (B) MgADP for LbPFK (pink) and D12A LbPFK (blue).  Each 
measurement was determined at [MgATP] = 15 mM for LbPFK and [MgATP] = 3mM 
for D12A LbPFK.  All data were fit to equation 2-4 to determine values given in Table 
4-1.  MgADP Data for LbPFK are from (82). 
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Table 4-2.   Steady state kinetic parameters for wild-type and D12A LbPFK at 25°C, pH 
8.0 
 
  PFK S.A. (U/mg)
a 
Kb (mM)
b 
Kia°
c
 Kiy°
c
 Kix°
c
 
Wild-type 250 0.34 ± 0.4 0.025 ± 0.001 27 ± 2 28 ± 8d 
D12A 28 0.049 ± 0.003 0.17 ± 0.02 3.0 ± 0.1 2.6 ± 0.2 
a S.A. = specific activity.  b Ka for MgATP was determined for WT LbPFK at 
[F6P]=3mM and D12A LbPFK at [F6P] = 5mM. c Values were determined at [MgATP] 
= 15mM for WT LbPFK and 3mM for D12A LbPFK. d (82)   
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MgADP in the experiment making the chances of MgADP binding to the active site 
highly unlikely. 
 
Steady-state Kinetics for T156A, H160A, H161A and H160A/H161A 
 Along with the interaction with R252, D12 also forms potential hydrogen bonds 
across the active site interface with two residues, T156 and H160.  In LbPFK there is  
also an H at position 161 which is an E in BsPFK and a N in EcPFK.  H161A does not 
come in contact with D12 in LbPFK but in the absence of H160 might interact with D12 
LbPFK.  Breaking of the D12-T156 interaction has been proposed to be involved in the 
effects of D12A (85).  Therefore T156A and H160A, as well as H161A, were introduced 
into LbPFK.  The double mutant H160A/H161A was also created to completely remove 
the histidine from across the interface from D12.  These mutants were analyzed for 
substrate binding as well as binding for the inhibitor PEP. 
 Table 4-3 gives the steady-state kinetic parameters for T156A, H160A, H161A 
and H160A/H161A LbPFK.  The specific activity for H160A and H161A were 
determined and when compared to LbPFK showed 2.5 and 1.3-fold decreases, 
respectively.  The specific activity for T156A and H160A/H161A was not determined 
because of the low protein expression for both mutants which caused each to only be 
purified to approximately 50% purity.  Low levels of purity would cause an inaccurate 
value for specific activity to be determined.   However, the kinetic assay used in 
measuring the steady state kinetic parameters is accurate enough that the low level of 
purity should not skew the results.  
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 Binding affinities for both F6P and MgATP were determined for the mutant 
H160A with MgATP binding being the same as wild-type, while F6P binding was 
diminished 11-fold.  Similar effects on F6P binding were seen with T156A and 
H160A/H161A, and these effects could all be attributed to the close proximity of these 
residues to the active site.  H161A showed a small effect on F6P binding, diminishing 
F6P binding 1.9-fold.  Therefore, the 10-fold decrease in F6P binding exhibited by 
H160A/H161A is due more by the H160A mutation than the H161A mutation.  Due to 
the similarity in MgATP binding for the active site interface variants, the same 
concentration of MgATP was used for all the variants when analyzing the binding 
affinity for both F6P as well as PEP.    
Figure 4-4 shows the analysis to determine the binding affinity for PEP to these 
active site interface mutants.  Upon mutating any of the residues across the active site 
interface from D12, no enhancement in PEP binding was observed (Table 4-3).  
H160A/H161A actually showed a slightly negative effect on PEP binding compared to 
native enzyme.  Lack of enhancement in PEP binding suggests that the breaking of the 
interaction between D12 and T156 and H160 does not contribute to the effect of D12A.  
Due to the lack of change in PEP binding, these mutants were not analyzed for binding 
to the allosteric ligand MgADP. 
 
Structural Analysis of D12A LbPFK 
 In hopes of better understanding the change in binding of the allosteric ligands 
to D12A LbPFK, the crystal structure of D12A LbPFK was determined to 2.3 Å  
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Table 4-3.  Steady state kinetic parameters for active site interface mutants of LbPFK at 
25°C, pH 8.0 
 
LbPFK S.A. (U/mg)
a,b 
Kb (mM)
c 
Kia° (mM)
d 
Kiy° (mM)
d 
T156A N.D. N.D. 0.390 ± 0.01 30 ± 7 
H160A 100 0.33 ± 0.03 0.330 ± 0.002 20 ± 4 
H161A 200 N.D. 0.047 ± 0.002 28 ± 3 
H160A/H161A N.D. N.D. 0.250 ± 0.007 37 ± 5 
WT 250 0.34 ± 0.4 0.025 ± 0.001 27 ± 2 
a S.A. = Specific Acitivity, b  N.D. = not determined.  Purity of T156A LbPFK and 
H160A/H161A LbPFK were low so an accurate specific activity for either was not 
determined.  c Kb for MgATP was determined at [F6P] = 3mM for WT LbPFK and 
LbPFK mutants.  d Determined for WT and all mutants at [MgATP] = 15mM. 
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Figure 4-4. Binding and allosteric response of PEP for active site interface variants 
compared to wild-type LbPFK at 25°C, pH 8.0.  The K1/2 for F6P was measured at 
various concentrations of PEP for LbPFK (pink), D12A (blue), T156A (purple), H160A 
(red), H161A (black) and H160A/H161A (cyan).  Each measurement was determined at 
[MgATP] = 15 mM for LbPFK and variants of LbPFK except for 3mM for D12A 
LbPFK.  All data were fit to equation 2-4 to determine values given in Table 4-2.     
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resolution. The D12A LbPFK crystals belong to the space group P6222 with unit cell 
parameters a=135.4 Å, b=135.4 Å and c=77.7 Å with a hexagonal shape.  The 
asymmetric unit contains a single monomer and the final structure was refined to R-
factor/R-free values of 17.48%/21.41%.  Each monomer contains 319 residues, 157 
water molecules and 12 sulfate ions.  The details of the final refinement parameters are 
shown in Table 4-1. 
Figure 4-5A shows the overall structure of the tetrameric form of D12A LbPFK 
looking along the dimer-dimer interface where the active sites are located.  Each 
monomer contains 3 sulfate ions with one bound to the active site, one bound to the 
allosteric site and one bound to the surface.  The sulfate bound to the surface of each 
monomer is likely a result of the crystallization conditions that contained 2.0M 
ammonium sulfate.  The sulfates bound to each of the binding sites are in a similar 
position as the sulfates bound to the wild-type LbPFK structure (82).  A close-up of the 
region around residue 12 is shown in Figure 4-5B.  A12 is highlighted in red and belongs 
to the yellow monomer with T156, H160 and H161 highlighted in cyan belonging to the 
pink monomer.  R252, also highlighted in cyan, interacts with F6P in the active site.  
Sulfate, shown in black, binds to the active site of D12A LbPFK in an orientation similar 
to that of the phosphate of F6P in BsPFK (84).  Due to proximity of residue 12 to the 
active site and the effect of D12A on the binding of the two substrates, a comparison was 
made between the active site residues of D12A to LbPFK (Figure 4-6). 
 Residues within the active site that are involved in F6P binding are highlighted in 
Figure 4-6A.  The location of the sulfate bound in the active site is also indicated.  When  
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Figure 4-5.  Crystal structure of D12A LbPFK to 2.2 Å resolution.  (A)  Tetramer of 
D12A with monomers colored pink, yellow, blue and green with sulfate (black) bound to 
all four active sites, all four allosteric sites and on the surface of each monomer.  (B)  
Close-up of region around residue 12 highlighting sulfate bound to the active site 
(black), A12 (red) with T156, H160, H161 and R252 (cyan). 
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Figure 4-6.  Active and allosteric site comparison between sulfate-bound wild-type and 
D12A LbPFK structures.  (A) Active site and (B) allosteric site comparison between 
wild-type (pink) and D12A (blue) LbPFK.  Highlighted are bound sulfates (black for 
D12A, grey for wild-type) with each residue labeled with the three-letter abbreviation 
and number.  RMSD between the two structures equals 0.169. 
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comparing D12A to LbPFK there are not many changes that occur within the active site.  
R252, R171 and R162 are the only residues that show any change in position upon the 
D12A mutation, but even these changes are minor.  There is also a slight change in the 
position of the sulfate within the active site but this could be due to the slight shift in the 
residues mentioned above.  Comparison of the amino acids involved in the binding of 
MgATP, based on binding of MgADP to BsPFK, show no change between the two  
crystal structures (84).  Lack of changes within the binding site indicates that the effects 
on both F6P and MgATP binding are not easily explained by changes within the 
structures of the active and allosteric sites of the enzyme.A comparison of the allosteric 
binding site between D12A and LbPFK was also performed and no major changes in the 
residues within the allosteric site were observed.  This lack of change within the 
allosteric site in unlike what is seen in BsPFK upon mutation of D12A in which several 
residues change position in order to better interact with the allosteric ligand (85).  
Differences between LbPFK and BsPFK are most likely due to lack of conservation in 
the allosteric binding site.  
In BsPFK, upon binding of the inhibitor-analog PG, the helix containing T156 
and H160 unwinds (84).  The unwinding of this helix causing T156 and H160 to move 
away from D12 causing any interactions between these residues to be broken.  D12A 
would also break these interactions indicating that the enhanced PEP binding in BsPFK 
could be due partially to the unwinding of this helix.  Figure 4-7 shows the regions 
surrounding residues 12 in both wild-type and D12A LbPFK.  When comparing the two 
structures the helix containing T156 and H160 stays intact and the distances between 
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these residues and residue 12 do not change dramatically.  Only the distance between 
residue 12 and R252 changes which could potentially affect the binding of F6P.  Overall, 
the relative lack of structural changes could be the reason that D12A only exhibits a 9-
fold change in PEP binding compared to the 100-fold effect seen in BsPFK (85). 
 
Discussion 
 Allosteric regulation of bacterial PFK has been explained by several different 
models.  One of the structural models indicates that a quaternary shift occurs along the 
active site interface upon binding of the inhibitor-analog PG (84).  This quaternary shift 
is accompanied by several small secondary structural changes including the unwinding 
of a helix, which contains T156 and H160, along the active site interface across the 
interface from D12.  In the allosteric binding site, a loop containing residues 211-215 
moves in concurrence with the quaternary shift upon binding of PG.  Allosteric 
inhibition by PEP was therefore thought to occur via this structural mechanism.  More 
recent studies have shown that mutating D12 to an alanine enhances PEP binding 100-
fold in BsPFK without changing the extent by which PEP inhibits (85).  Structural 
studies of D12A BsPFK indicate that upon the D12A mutation, the helix which contains 
T156 and H160 unwinds in a similar fashion as what was seen upon binding of PG.  
These studies suggest that breaking the interactions between D12 and the residues across 
the active site interface are important for PEP binding to the allosteric site.  LbPFK, 
unlike BsPFK and EcPFK, has very weak binding affinity for both the allosteric ligands 
PEP and MgADP.  Overall the structure of LbPFK is similar to that of BsPFK and  
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Figure 4-7.  Comparison of distances between T156, H160 and R252 with residue 12 in 
wild-type and D12A LbPFK.  Enhancement of active site interface between the pink and 
yellow monomers.  Distances between T156, H160 and R252 and residue 12 were 
measured in (A) wild-type LbPFK and (B) D12A LbPFK structures.  Highlighted are 
residues 12 (red), R252, T156 and H160 (cyan).   
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EcPFK with the exception of the allosteric binding site (82-84).  
Since mutating D12 in BsPFK enhanced binding affinity for PEP, the same 
mutation was introduced into LbPFK.  D12A LbPFK exhibited weaker binding for F6P 
with enhanced binding for MgATP to the active site as well as PEP and MgADP binding 
to the allosteric site.  Since D12 interacts with R252, an active site residue which 
interacts with the phosphate of F6P, diminishing F6P binding upon introducing D12A is 
most likely due to the breaking of the interaction between D12 and R252.  Breaking of 
this bound could reposition R252 to not interact with F6P as strongly and comparing the 
position of R252 in the structure of D12A LbPFK to wild-type LbPFK, it is clear that 
R252 does move away from the bound sulfate in the active site.  This sulfate is bound 
where the phosphate of F6P would be bound so it serves as a point of comparison in the 
LbPFK structures.  The effect of MgATP binding is harder to rationalize structurally 
since none of the residues which would interact with MgATP change position upon the 
introduction of D12A into LbPFK.  Enhancement in MgATP binding could however be 
explained by the antagonistic relationship between F6P and MgATP binding.  When one 
is diminished the other is enhanced. 
 In LbPFK, like BsPFK, D12A did enhance the binding of the allosteric inhibitor 
PEP though not to the same extent.  D12A LbPFK only showed a 9-fold enhancement 
compared to the 100-fold enhancement seen in BsPFK (85).  The smaller enhancement 
is likely related to the lack of structural changes in D12A LbPFK compared to LbPFK 
which are present when comparing D12A BsPFK to BsPFK.  As mentioned earlier, 
D12A BsPFK causes a major shift to occur along the active site interface which is 
 79 
accompanied by the unwinding to a helix that contains T156 and H160.  In D12A 
LbPFK the helix containing T156 and H160 remains intact, and the distances between 
the residues and residue 12 do not change.  It is therefore unlikely that the breaking of 
these interactions causes the enhanced binding of PEP to the allosteric site in LbPFK. 
 In order to further understand the role in the interactions between D12 and T156 
and H160 across the active site interface, T156A and H160A were introduced into 
LbPFK.  Both of these showed weaker F6P binding similar to D12A but did not show 
any enhancement in PEP binding.  LbPFK contains an H at position 161 which could 
take the place of H160 in the event that it is missing, so H161A as well as 
H160A/H161A were introduced and neither mutant showed enhanced PEP binding 
compared to LbPFK.  H161A did not affect F6P binding to the same extent as the other 
mutation and H160A/H161A had a similar binding affinity for F6P as that of H160A 
indicating that H160A plays the role in the decrease in F6P binding for the double 
mutant.  These mutations further support the hypothesis that the breaking of interaction 
between D12 and T156 or H160 is not involved in the enhancement of PEP binding seen 
in D12A LbPFK. 
The affinity of D12A LbPFK for the allosteric activator MgADP was also 
determined.  As was the case for PEP, D12A showed an enhanced binding for MgADP 
compared to LbPFK as well as an inhibitory response.  In EcPFK MgADP acts as an 
allosteric activator so it is interesting that MgADP appears to be acting as an allosteric 
inhibitor in both LbPFK as well as D12A LbPFK.  One explanation could be that 
MgADP acts as a product inhibitor since MgADP is a product of the reaction.  Product 
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inhibition by MgADP is unlikely since throughout the experiment MgATP is saturating 
at the active site, and since MgATP is also present at equal molar concentrations to 
MgADP competing with MgADP for binding at the active site.  Therefore the inhibition 
of F6P binding resulting from MgADP binding to the allosteric site is most likely 
allosteric inhibition.  Since there is no change in the position of the allosteric site 
residues upon mutating D12, it is harder to explain the enhanced binding for PEP and 
MgADP to this site as well as the inhibitory effect of MgADP.   
 The effects of D12A are also interesting given the distances between D12 and the 
four allosteric binding sites which are 15, 20, 33 and 41 Å in LbPFK.  With the shortest 
distance being 15 Å, it is possible that there is a network of residues from D12 to the 
allosteric binding site in LbPFK that becomes interrupted with the introduction of D12A.  
In BsPFK, the link appears to involve a large structural change combined with smaller 
secondary changes in both regions.  One residue that appears to link the two sites within 
the structures is T158 which interacts with the allosteric site residues H215 in the 
substrate-bound form of BsPFK but moves to interact with D12 in the PG-bound 
structure.  For this reason, T158A was introduced into BsPFK but showed no 
enhancement in PEP binding as well as a decrease in the extent of inhibition by PEP 
(85).  Due to these results and LbPFK having S158 as well as H215, it is unlikely that 
residue 158 plays as significant a role in LbPFK.   
Another possible explanation for the weaker response of D12A in LbPFK 
compared to BsPFK is the lack of conservation within the allosteric binding site.  Since 
the weak binding for PEP is likely due to the weak conservation of residues within the 
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allosteric binding site, combining changes there with D12A could potentially cause a 
more dramatic effect on PEP as well as MgADP binding.  Therefore mutations must be 
made within the allosteric site to determine the potential role of these residues as well as 
combining these mutations with D12A in hopes of a better understanding of the overall 
weak binding for allosteric effectors to LbPFK. 
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CHAPTER V 
SINGLE AND LONG CASSETTE MUTATIONS WITHIN THE ALLOSTERIC SITE 
OF LbPFK 
 
Phosphofructokinase (PFK) catalyzes the first committed step in glycolysis 
performing a phosphoryl transfer from MgATP to fructose-6-phosphate (F6P) forming 
MgADP and fructose-1,6-bisphosphate.   Structurally, PFK is a homo-tetramer 
organized as a dimer of dimers.  It contains four active sites along one dimer-dimer 
interface with the allosteric sites along the other dimer-dimer interface.  PFK from most 
bacterial sources is allosterically regulated by two ligands, the inhibitor 
phospho(enol)pyruvate (PEP) and the activator MgADP.   In contrast, the PFK from 
Lactobacillus delbrueckii subspecies bulgaricus (LbPFK) exhibits weak binding affinity 
for the allosteric ligands, approximately 25 mM for PEP and MgADP, as well as 
inhibition at very high concentrations (82).  These differences allow LbPFK to be used 
as a model for understanding the molecular basis for binding of PEP and MgADP as 
well their allosteric responses. 
LbPFK shows high sequence identity to both EcPFK (47% identity with 66% 
similarity) and BsPFK (56% identity with 74% similarity) and has an overall 
conservation in structure (Figure 5-1).  In 2005, the first structure of LbPFK was solved 
to 1.86 Å resolution with sulfate bound to all eight binding sites, four being the active 
sites and four being the allosteric sites (82).  In EcPFK, several residues were identified 
to be important for MgADP binding at the allosteric site.  These residues include D59,  
 83 
 
Figure 5-1.  Amino acid sequence alignment of LbPFK, TtPFK, BsPFK and EcPFK.  
Sequences were aligned using MacVector® 7.0.  Highlighted in green are amino acid 
residues involved in binding to the allosteric site for MgADP in EcPFK and PG in 
BsPFK with the exception of 211.  Highlighted in red are the single mutations made 
from the residues in LbPFK to the corresponding residue in TtPFK with the large 
cassette mutations in blue.  The numbering of the amino acid residues in the figure is 
according to the EcPFK sequence but the numbering in the text is according to the 
LbPFK sequence.   
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E187 and R21, R25, R54, and R154 (83).  BsPFK was crystallized with the inhibitor-
analog phosphoglycolate (PG) and most of the residues involved in MgADP binding in 
EcPFK are also involved in PG binding with the addition of R211 and K213 (84).  
Residue 54 is a valine in BsPFK but is an arginine in EcPFK therefore R211 takes the 
place of the missing positive charge at position 54 in BsPFK.   
The allosteric site of LbPFK is similar to EcPFK and BsPFK in that it contains 
D187, K213 and R21, R25 and R154 (Figure 5-1).  However, LbPFK is different at 
positions 54 and 211, having a S at both positions as well as position 59 where an H 
replaces a D.  Another major difference within the allosteric site of LbPFK compared to 
EcPFK and BsPFK is the residue at position 214.  LbPFK has a D while EcPFK and 
BsPFK have lysines.  In EcPFK, the mutation K214D exhibits diminished binding for 
MgADP and PEP as well as weaker allosteric responses in both cases (84, 109).   R25, 
R211 and K213 were all mutated to glutamates in BsPFK and showed diminished 
binding for PEP and weakened allosteric inhibition (73, 110).   
Schirmer and Evans in 1990 identified the involvement of residues 213-215 in 
the transition of BsPFK from the substrate-bound R-state to the inhibitor-bound T-state 
(84).  In that study, the substrate-bound structure of BsPFK with F6P and MgADP 
bound to the active site as well as MgADP bound to the allosteric site was compared to 
the inhibitor bound structure with the PEP analog PG bound to the allosteric site (84).  
One of the main structural changes identified between these two structures is a “hinge 
movement” involving the loop containing residues 213-215 which pivots at residues 212 
and 216.  In the absence of ligand, the binding site is open but when either effector binds 
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the loop closes so that the ligand is packed tightly within the site.  According to this 
model, the extent of the hinge movement is dependent on the size of the effector ligand 
with PG inducing a smaller change than MgADP.  Another major change is the 
conformation of E187 that is coordinated to the Mg ion of MgADP in the substrate-
bound BsPFK.  Upon binding of PG, E187 is rotated 140° where the side-chain is no 
longer in contact with the ligand but is sandwiched between an α-helix and a β-sheet.  It 
is possible that the differences in the residues found within these regions of the allosteric 
binding site of LbPFK inhibit these movements and interactions causing weaker binding 
affinity for both MgADP and PEP.  
 TtPFK, another allosterically regulated PFK, is similar in sequence to EcPFK 
(46% identity with 62% similarity), BsPFK (57% identity with 70% similarity) and 
LbPFK (46% identity with 60% similarity).  It has the highest binding affinity for the 
allosteric inhibitor PEP of this group of PFKs, with a dissociation constant equal to 3 
µM.  This is 20-fold tighter than BsPFK and 9,000-fold tighter compared to LbPFK.  No 
crystal structure is available for TtPFK, but a sequence comparison to BsPFK and 
EcPFK shows that it contains E187, K214 as well as the essential R21, R25, R154, and 
R211 in order to bind the allosteric ligands.  TtPFK shows differences within the 
allosteric site residues compared to BsPFK and EcPFK with a R at position 55, a N at 
position 59 and a S at position 215.  N59 would not form the interactions between the 
allosteric ligands and the D59 in EcPFK and BsPFK and the same would be true with 
S215 compared to H215.  R55, which is an E in EcPFK and a G in BsPFK, introduces an 
extra positive charge in the allosteric binding site facilitating the binding of the 
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negatively charged MgADP and PEP in TtPFK.  R55 when changed to an E, the 
corresponding residue in LbPFK, diminished the binding for PEP 500-fold compared to 
wild-type TtPFK (78).  N59D and S215H were also introduced into TtPFK and both 
exhibited differences in PEP binding and allosteric inhibition, respectively (78). 
   In this chapter, amino acids in the allosteric site of LbPFK that were not 
conserved compared to the allosteric PFKs were mutated to the corresponding residues 
in TtPFK.  These residues were changed alone and in combination and characterized for 
their ability to bind the inhibitor PEP.  Single residue changes were made from LbPFK 
to TtPFK at positions 55, 59, 211, 214, 215 and 216 with no enhancement in PEP 
binding measured.  A combination mutant was designed which included residues 211, 
214 and 215, but this mutant was unstable and therefore could not be studied.   
   Another approach utilized in this study was to introduce long cassettes of 
mutations into LbPFK substituting the residues in LbPFK for the corresponding residues 
in TtPFK (Figure 5-1).   Regions containing residues 206-218 (substitution 1, PFKs1) as 
well as 52-61 (substitution 2, PFKs2) were mutated as two single cassettes and mutated 
simultaneously to form a double cassette variant (PFKs1s2).  The double cassette variant 
contains all the residues involved in binding for MgADP to EcPFK and PG to BsPFK 
(83, 84, 111).  This is the first time this approach has been used for the study of PFK in 
the Reinhart lab. 
In a previous study by Byrnes, et. al., a chimeric enzyme was created using 
BsPFK and EcPFK by fusing the first 122 amino acids of BsPFK with the remaining C-
terminal residues of EcPFK (112).  PEP did bind to this chimeric PFK but no allosteric 
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inhibition was measured, even though the allosteric binding site was exactly that of 
EcPFK.  Byrnes, et. al. hypothesized that the lack of allosteric inhibition was due to the 
fact that the structural changes within BsPFK upon PG binding were absent in the 
chimeric enzyme.  Single mutations of residues 55, 59, 211, 214, 215 and 216 as well as 
large cassette mutations PFKs1 and PFKs2 were introduced into the allosteric binding 
site with the goal of enhancing PEP binding.  None of the single mutants along with the 
cassettes PFKs1 and PFKs2 enhanced binding for PEP when compared to wild-type 
LbPFK.  However, PFKs1s2 exhibited a 9-fold enhancement in PEP with no change in 
the binding affinity for MgADP.  The results of PFKs1s2 indicate a need for multiple 
mutations within the allosteric binding site to enhance binding for the inhibitor PEP. 
 
Methods 
Site-directed Mutagenesis 
The protocol used for site-directed mutagenesis is explained in detail in Chapter 
II.  The template strands for the single variants are shown in Figure 5-2. 
RKS LbPFK, which combines the mutations S211R, D214K and G216S, was 
created by changing each amino acid in a sequential manner.  Due to the fact that 211, 
214 and 216 are in close proximity to one another, another set of oligos were needed to 
make sure the new mutation was introduced without disturbing the mutations already 
present within the gene.  Figure 5-2 shows the template strands for the set of 
oligonucleotides to introduce the mutations D214K and G216S into pKK223-PFK  
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E55R:  GAC ATT TTC CCA TTG GAA AGT CGT GAC GTA GCC CAC TTG ATC 
H59N:  GT GAA GAC GTA GCC AAC TTG ATC AAT GTT TCC GGT AC 
S211R:  G CAA GCC CAG GAA CGT GGC AAG GAC CAC GG 
D214K:  C CAG GAA AGC GGC AAG AAG CAC GGT TTG GTA GTT   
H215S:  G GAA AGC GGC AAG GAC AGC GGT TTG GTA GTT GTT G 
G216S:  GAA AGC GGC AAG GAC CAC AGC TTG GTA GTT GTT GC 
D214K/G216S for S211R:  
C CAG GAA CGT GGC AAG AAG CAC AGC TTG GTA GTT GTT GCT GAA G 
PFKs1:  GCC AAC CGG CTC GAG GCC TCC CAG AGG CGG GGG AAG AAG 
AGC TTCC ATC GTG GTT GTT GCT GAA G 
PFKs2: GC GAC ATT TTC CCA TTG GGG GTG CGG GAC GTG GCC AAC ATC 
AAT GTT TTC CGG TAC C  
Figure 5-2.  Template strands used for site-directed mutagenesis to create the allosteric 
site mutations in LbPFK.   For each LbPFK variant (bolded), the DNA sequence for the 
template strand is shown and was used along with the complementary strand to introduce 
the change in the DNA sequence.  For E55R, H59N, S211R, D214K, H2215S, G216S 
and D214K/G216S for S211R, the codon(s) that was changed is underlined.  For PFKs1 
and PFKs2, the sequence underlined make up the template strand used to delete the 
sequence from LbPFK and the whole template strand shown above was used to 
introduce the new sequence from TtPFK into the plasmid containing LbPFK. 
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containing the S211R mutation.  
For the long cassette mutations, two separate mutagenesis reactions were 
performed.  The first one deleted the sequence of DNA from the LbPFK gene and the 
second introduced the corresponding sequence from TtPFK into the LbPFK gene.  In the 
deletion reaction for PFKs1, an oligo was designed which contained 12 bases upstream 
of the sequence to be deleted along with 13 bases downstream that when combined 
formed an oligo 25 bases long.  The 25 base oligo along with the complementary strand 
deleted the DNA sequence corresponding to residues 52-61 from the LbPFK gene.  
Deletion of PFKs2 involved an oligonucleotide that combined 14 bases upstream with 
16 bases downstream of the deletion to form a 30 base oligonucleotide which when 
paired with the complementary strand deleted the DNA sequence corresponding to 
residues 206-218 from the LbPFK gene.  Then for the insertion reaction, another oligo 
was designed which contained the DNA sequence to be inserted into the LbPFK gene 
between the bases which were upstream and downstream of the sequence that had been 
deleted.  Shown below are the template strands for the insertion of the DNA sequence 
from TtPFK into the LbPFK gene with the underlined bases indicating the DNA 
sequence used to form the deletion appropriate deletion oligonucleotide.  Along with the 
complementary strand, the oligonucleotides in figure 5-2 were used to create PFKs1 and 
PFKs2. 
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Protein Purification of Allosteric Site Mutants 
 The majority of the mutants, expressed in MRL277, were grown in similar 
conditions to those for LbPFK with the exception of PFKs1s2.  This mutant was grown 
in LB broth with 0.1 g/mL ampicillin at 37 °C to an optical density of 0.6, cooled to 25 
°C, induced with 0.5 mM IPTG and grown at 25 °C for 19 hours.  The cells were then 
harvested and stored at -80 °C.   
 The majority of the mutants were purified under the same conditions as LbPFK 
with the exception of D214K, S211R, G216S, PFKs1 and PFKs2.   Due to instability of 
the protein, D214K and S211R were purified in the presence of 1 mM F6P.  In the case 
of G216S and PFKs2, a 0-2.5 M NaCl gradient was needed to elute the mutant proteins 
off the Mimetic Blue I column. 
In the case of D214K, after the Mimetic Blue I column additional steps were 
needed to obtain a purified sample.  After eluting the mutant PFK off the Mimetic Blue 1 
column using a 0-1 M NaCl gradient in Buffer A-1 (Buffer A + 1 mM F6P), the 
fractions containing PFK were dialyzed against Buffer A-1 and then loaded onto a DE52 
anion-exchange column, washed with at least 5 column volumes of Buffer A-1 and 
eluted with a 0-0.5 M NaCl gradient in Buffer A-1.  Fractions containing the PFK were 
then pooled and dialyzed against Buffer A-1, pH 8.0.  Finally the sample was loaded 
onto a MonoQ anion-exchange column at pH 8.0, washed with 2 column volumes of 
Buffer A-1 and eluted with a 0-1 M NaCl gradient in Buffer A-1.  The fractions 
containing the mutant PFK were pooled and dialyzed into Buffer B-1 (Buffer B + 1 mM 
F6P), concentrated and stored at 4 °C. 
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In the case of S211R, after eluting the mutant PFK off the Mimetic Blue 1 
column with a 0-1 M NaCl gradient, the pooled fractions were dialyzed into Buffer A-1 
pH 8.0, loaded onto a MonoQ anion-exchange column, washed with 2 column volumes 
of Buffer A-1 and eluted with a 0-1 M NaCl gradient in Buffer A-1.  The fractions 
containing the purified mutant PFK were pooled, dialyzed into Buffer B-1, concentrated 
and stored at 4 °C.            
 For PFKs1s2, the purification was performed at 4°C in the presence of 1 mM 
F6P.  The crude lysate was applied to a 100 mL Mimetic Blue A column and washed 
with 1200 mL Buffer A-1.  The majority of the protein eluted off the column after 600-
1000 mL of wash buffer had been applied to the column.  The fractions sample was 
adjusted to 8.5, and the sample was applied to a 20 mL pre-equilibrated High-Q anion 
exchange column.  The column was washed with Buffer A-1, pH 8.5 and the protein was 
eluted with a 0-1M NaCl gradient.  The fractions containing PFK activity were pooled, 
dialyzed into Buffer B-1 and stored at 4 °C.  All experiments with this variant PFK were 
performed with the sample on ice. 
 
Results 
Allosteric Site Comparison of Bound PFKs 
 WT LbPFK has been shown previously to have weak binding affinity for the 
allosteric ligands PEP and MgADP (82, 97).  A crystal structure of WT LbPFK was 
recently determined to 1.83 Å resolution with phosphate groups bound in the four active 
sites and four allosteric sites (see Chapter III).  The determination of this structure has 
 92 
allowed for structural comparison with other ligand bound allosteric PFKs, which 
demonstrate tighter affinities for both PEP and MgADP (83, 84, 113, 114).  PFK is a 
tetramer which is organized as a dimer of dimers.  The active sites lie along one dimer-
dimer interface and the allosteric sites span the other dimer-dimer interface.  The active 
sites and allosteric sites share amino acids from two separate monomers making it 
necessary for the tetramer to be intact for proper binding to both the active and allosteric 
sites.  By overlaying the dimers which are formed along the allosteric site interface from 
phosphate-bound LbPFK, PEP-bound D12A BsPFK (which is similar in structure to the 
PG-bound structure of WT BsPFK) and MgADP-bound EcPFK (83-85), it is evident that 
the over-all secondary structure of the dimer is similar between the three (Figure 5-2A).  
There are slight shifts in some of the secondary structural elements in BsPFK compared 
to LbPFK or EcPFK, that occur along with the large quaternary shift proposed by 
Mosser and Reinhart to be involved in binding of PEP to the allosteric site (85).  
A structural comparison between LbPFK, BsPFK and EcPFK indicates that 
LbPFK contains several residues which are different to the corresponding residues in 
BsPFK and EcPFK (Figure 5-3B-D).  The conserved residues between the three PFKs 
compared include R21, R25, R154, K213 and H215.  Residue 187 is slightly different 
with BsPFK and EcPFK having an E and LbPFK having a N. When MgADP is bound to 
the allosteric site of BsPFK, E187 is in a folded conformation and coordinates with the 
Mg ion.  Once PG binds to the allosteric site, the χ1 torsion angle rotates 140° causing 
the side-chain to face away from the ligand (82).  When mutated to an alanine, E187 
actually activates PEP in the presence of MgATP and MgADP has no effect on F6P 
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binding in EcPFK (108, 111).  In LbPFK, D187 has a shorter side-chain making the  
coordination of the Mg ion weaker and therefore weakening the binding affinity for 
MgADP (82).   
The major differences seen within the allosteric site include the loop containing 
residues 211-215 as well as the α-helix containing residues 54-55 that is located across 
the interface from 211-215.  Residues 54 and 55 are not well conserved between the 
three PFKs with LbPFK having a S at 54 and an E at 55, BsPFK having a V at 54 and a 
G at 55, and EcPFK having an R at 54 and Y at 55.  Y55 shows strong base-packing 
with the adenosine ring of MgADP in EcPFK and the absence of this interaction could 
potentially affect the ability of MgADP to bind as tightly in LbPFK.  The other residue 
that is different between LbPFK and the two allosteric PFKs is the histidine at position 
59.  Both BsPFK and EcPFK have an aspartate at that position that forms a hydrogen 
bond with the ribose O3 of ADP and the absence of this hydrogen bond would 
potentially weaken binding for MgADP (82).   
Within the loop containing residues 211-215, there are some major differences in 
LbPFK.  The number of positive residues decreases from 4, which is found in both 
EcPFK and BsPFK, to 2 in LbPFK.  In BsPFK, the side-chain of K214 changes positions 
from pointing away from the allosteric ligand in the substrate-bound form to pointing 
towards PG in the inhibitor-bound form of BsPFK.  K214 also interacts with PEP via a 
backbone hydrogen bond and any change in the position of the side-chain or interactions  
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Figure 5-3.  Structural comparison between phosphate-bound LbPFK, PEP-bound D12A 
BsPFK and MgADP-bound EcPFK.  (A) Overlay of allosteric interface PFK dimer with 
phosphate-bound LbPFK in black, PEP-bound D12A BsPFK in pink and MgADP-bound 
EcPFK in green.  Ligands are shown in both sites.  Allosteric site with specific residues 
highlighted from (B) phosphate-bound LbPFK. (C) PEP-bound D12A BsPFK. (D) 
MgADP-bound EcPFK.  Positively charged residues highlighted in blue and negatively 
charged residues highlighted in red.   
 
 
 
  
 95 
between K214 and other residues could have an effect on this backbone interaction.  In 
LbPFK there is an D at position 214 that is opposite in charge to a lysine and has a much 
shorter side-chain.  Any interactions between K214 and other residues would not be 
present in LbPFK and the interactions between D214 and other residues would be much 
different.  LbPFK is also missing a positive charge at position 211 which is present in 
both BsPFK and EcPFK.  In BsPFK, R211 interacts with both PEP and MgADP and 
interacts with a water molecule in the absence of any ligand (85).  A S at this position 
would interrupt any interaction with either ligand and would therefore have an effect on 
ligand binding. 
 
Single Mutations within Allosteric Site 
E55, H59, S211, D214, H215 and G216 were each changed to the corresponding 
residue in TtPFK forming the LbPFK mutants E55R, H59N, D214K, H215S and G216S.  
These modified PFKs were analyzed for their ability to bind F6P and PEP as well as 
their ability to exhibit allosteric inhibition.  The kinetic parameters Vmax and K1/2 were 
determined for F6P binding for each mutant by fitting initial velocity data to equation 1 
(Table 5-1).   Vmax values for almost all of the single mutants were close to that for the 
wild-type enzyme with the exception being G216S, which has a maximal activity of 1.3 
U/mg.  The effect of G216S on maximal activity is interesting since the residue is 17 Å 
from the active site, and the binding for F6P is similar to LbPFK.  To compare the 
binding of F6P between the mutants and the wild-type enzymes, the free energy of 
binding (ΔGa°) was calculated using equation 2-5.  Figure 5-4B shows that the binding 
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of F6P to the single allosteric site variants are similar to LbPFK and TtPFK, both 
approximately -6 kcal/mol, and the mutations do not greatly affect the binding of F6P to 
the active site.  The binding for MgATP was also analyzed since TtPFK has a 58-fold 
tighter Kb (Michaelis constant) compared to LbPFK (78).  For all the mutants analyzed, 
the dissociation constant for MgATP was not altered significantly compared to WT 
LbPFK (Table 5-1).  From these data, it appears that the single mutations introduced in 
the allosteric binding site have no significant effect on ligand binding to the active site of 
LbPFK. 
To examine the extent of binding and allosteric inhibition for the wild-type 
enzyme and single mutants, the K1/2 for F6P was determined at various concentrations of 
PEP.  Figure 5-4A shows the replot of the K1/2 for F6P as a function of PEP, and fitting 
the data to either equation 2-3, in the case of TtPFK, or equation 2-4 for LbPFK and the 
LbPFK mutants, yields the dissociation constant for F6P (Kia0) and PEP (Kiy0) in the 
absence of the other ligand.  When saturation with PEP is evident, then the coupling 
constant (Qay) between F6P and PEP can be determined.  Qay describes both the 
magnitude and the nature of the allosteric response (88).  The weak binding affinity for 
PEP in WT LbPFK does not allow for the determination of Qay, and none of the single 
allosteric site mutations enhanced binding enough for that value to be determined.  As 
with F6P, the ΔG° was determined for PEP binding (ΔGy°) so that a comparison could 
be made between the wild-type PFKs and the variants.  ΔGy° is quite different when 
comparing LbPFK to TtPFK with values of -2.2 ± 0.05 kcal/mol and -7.5 ± 0.02 
kcal/mol respectively.  The change in ΔGy° corresponds to a 9,000-fold difference in 
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Table 5-1.  Steady state kinetic parameters for wild-type and variant PFKs at 25°C, pH 
8.0 
 
PFK S.A.
a
 (U/mg) Kb
 
(mM)
b,c 
Kia° (mM) Kiy° (mM) Qay
d 
WT LbPFK 240 0.34 ± 0.04 0.025 ± 0.0001 27 ± 2 N.A. 
E55R 280 N.D. 0.043 ± 0.0007 33 ± 3 N.A. 
H59N 250 N.D. 0.025 ± 0.0004 38 ± 2 N.A. 
S211R 200 0.35 ± 0.02 0.050 ± 0.001 23 ± 1 N.A. 
D214K 180 0.37 ± 0.02 0.063 ± 0.001 29 ± 2 N.A. 
H215S 200 N.D. 0.029 ± 0.0005 37 ± 3 N.A. 
G216S 1.3 0.29 ± 0.02 0.038 ± 0.001 21 ± 2 N.A. 
PFKs1 260 0.15 ± 0.01 0.035 ± 0.0006 42 ± 3 N.A. 
PFKs2 200 N.D. 0.042 ± 0.0008 32 ± 3 N.A. 
PFKs1s2 240 0.27 ± 0.001 0.045 ± 0.001 2.7 ± 0.1 N.A. 
WT TtPFK
e 45 0.0059 ± 0.0005 0.027 ± 0.0006 0.003 ± 0.0001 0.068 ± 0.002 
a S.A. = specific activity, b Kb for MgATP at [F6P] = 5 mM, c N.D. = not determined, d 
N.A. = not assessable, e (78) 
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Figure 5-4.  Effect of single variants on binding of F6P and PEP in LbPFK at 25°C, pH 
8.0.  The binding affinity (K1/2) for F6P was measured as a function of the allosteric 
inhibitor PEP.  (A)  Replot of K1/2 for F6P as a function of PEP with LbPFK (black), 
E55R (green), H59N (purple), S211R (pink), D214K (blue), H215S (red), G216S (cyan) 
and TtPFK (grey).  Data for TtPFK was fit to equation 2-3 to determine the dissociation 
constant for F6P (Kia0) and PEP (Kiy0).  Since saturation could not be reached with PEP 
for LbPFK and LbPFK mutants, data were fit to equation 3.  To compare the extent of 
ligand binding, the free energy of binding for (B) F6P (ΔGa°) and (C) PEP (ΔGy°) were 
calculated using equation 2-5.  All experiments were performed at 25 °C at [MgATP] = 
15 mM. 
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PEP binding.  None of the single mutants enhanced binding affinity for PEP to the 
allosteric site when compared to WT LbPFK.  Several actually had a negative effect on 
PEP binding with E55R and H59N having the weakest binding at 36 ± 4 mM and 38 ± 2 
mM respectively.  The mutations at 211, 214, 215 and 216, which are located across the 
dimer-dimer interface from 55 and 59, all showed similar PEP binding as LbPFK.  These 
data indicated that a single mutation within the allosteric binding site is not sufficient to 
enhance PEP binding.  
 
Large Allosteric Site Substitutions  
Since no large change in PEP binding is seen with the single allosteric site 
mutations, combination mutations were designed in which several amino acid residues 
were changed simultaneously.  Initially double, triple and even quadruple mutants were 
designed including various combinations of the residues mentioned above.  However 
most of these mutations were unstable and therefore could not be analyzed (data not 
shown).  In order to circumvent this problem, long cassettes of mutations had to be 
introduced.  Two regions of the allosteric site were chosen, one including residues 55 
and 59 and one including residues 211-216.  Making these long cassette mutations 
would keep the secondary structure the same as in LbPFK and lead to improved protein 
stability.  So, PFKs1 and PFKs2 were designed and substituted the residues included 
between 52-61 and 206-218 in LbPFK to the corresponding residues from TtPFK 
(Figure 5-1).  The changes were easily introduced using the protocol from the 
Stratagene® Quik-Change Mutagenesis Kit.  Only two reactions were needed, the first 
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of which deleted the DNA sequence from the parent plasmid and a second that replaced 
the deleted sequence with the new DNA sequence from the TtPFK gene.  The two 
mutants were also combined to form PFKs1s2.  These three mutants were analyzed to 
determine the binding affinity for both substates F6P and MgATP as well as the 
allosteric inhibitor PEP.  PFKs1, PFKs2 and PFKs1s2 had binding constants for F6P 
ranging from 35 to 45 µuM (Table 5-1).  These are approximately 1.5-fold weaker than 
LbPFK and TtPFK.  The Kb (Michaelis constant) for MgATP was 1.6-fold tighter for 
PFKs1s2 and 3-fold tighter for PFKs1 when compared to LbPFK.  The Ka was not 
determined for PFKs2.   
 These Kb values are closer to those of LbPFK than those of TtPFK suggesting 
that these residues are not indirectly involved in the binding of MgATP.  The specific 
activities (S.A.) of the long cassette mutations were also more comparable to LbPFK 
than to TtPFK, ranging from 200 to 260 U/mg (Table 5-1).  Similar substrate binding 
and S.A. for these mutations compared to LbPFK suggest that the amino acids changed 
within the allosteric binding site don’t exhibit large effects at the active site. 
These variants were analyzed for their ability to bind PEP to the allosteric site 
(Figure 5-5A).  As with the single mutants,  ΔGa° and ΔGy° were calculated and used to 
compare the mutants with both LbPFK and TtPFK.  PFKs1 exhibited weaker PEP 
binding compared to WT LbPFK with a ΔGy° value of -1.9 ± 0.04 kcal/mol compared to 
-2.2 ± 0.04 kcal/mol.   The change in ΔGy° corresponds to a 1.7-fold decrease in PEP 
binding.  PFKs2 also exhibited a weakened PEP binding.  However, when the two 
mutants were combined to form PFKs1s2, PEP binding was enhanced approximately 10- 
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Figure 5-5.  Effect of long cassette variants on binding of F6P and PEP in LbPFK at 
25°C, pH 8.0.  The binding affinity (K1/2) for F6P was measured as a function of the 
allosteric inhibitor PEP.  (A)  Replot of K1/2 for F6P as a function of PEP with LbPFK 
(black), PFKs1 (green), PFKs2 (purple), PFKs1s2 (pink) and TtPFK (grey).  Data for 
TtPFK was fit to equation 2-3 to determine the dissociation constant for F6P (Kia0) and 
PEP (Kiy0).  Since saturation could not be reached with PEP for LbPFK and LbPFK 
variants, data were fit to equation 2-4.  To compare the extent of ligand binding, the free 
energy of binding for (B) F6P (ΔGa°) and (C) PEP (ΔGy°) were calculated using 
equation 2-5.  All experiments were performed at 25 °C at [MgATP] = 15 mM. 
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fold compared to WT LbPFK.  This is the first modification introduced within the 
allosteric binding site to exhibit an increase in the binding affinity for the inhibitor PEP.   
ΔGy° for PFKs1s2 was -3.5 ± 0.02 kcal/mol, a change of 1.3 kcal/mol relative to LbPFK.  
This ΔGy° is still not as great as seen in TtPFK, whose -7.5 ± 0.02 kcal/mol is the 
greatest of the four bacterial PFKs studied in the Reinhart lab (78). 
Another interesting characteristic seen with PFKs1s2 is the change in the Hill coefficient 
(nH) for F6P upon the binding of PEP to the allosteric site.  In LbPFK, the nH for F6P 
does not change significantly with increasing concentration of the inhibitor PEP (Figure 
5-6).  The nH for F6P also showed no change for the variants PFKs1 and PFKs2.  
However, in the case of PFKs1s2, as the concentration of PEP is increased the nH for 
F6P also increases.  In the absence of PEP the nH is similar to that of LbPFK, around 1.2, 
but at the highest concentration of PEP, 80 mM, the nH is close to 4.  This dependence of 
nH for F6P on the concentration of PEP is also seen in TtPFK and the pattern is similar to 
that seen with PFKs1s2 (Figure 5-6).  The nH starts out around 1.5 at low concentration 
of PEP and stops at a value of 2.6 at saturating concentration of PEP in TtPFK.  The nH 
begins increasing around the concentration of PEP which is equal to the Kiy° in both 
TtPFK and PFKs1s2 and stops changing close to the saturating concentration of PEP.  
Any further increase in the nH for PFKs1s2 is unlikely since any number above 4 would 
be greater than the number of binding sites for F6P in the tetramer.  It is also unclear 
how the nH would further change at PEP concentrations above 80mM since saturation of 
PEP could not be reached for PFKs1s2.   
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Figure 5-6.  Hill coefficient for F6P as a function of PEP concentration at 25°C, pH 8.0.  
Titration curves for F6P were performed at various concentration of PEP and the data fit 
to equation 1 to determine the hill coefficient for F6P.  A replot of the hill coefficient at 
each concentration of PEP is shown for LbPFK (black), PFKs1s2 (pink) and TtPFK 
(grey).  All experiments were performed at 25°C, pH 8.0.   
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Due to the enhanced binding for PEP to the allosteric site of PFKs1s2, the 
binding affinity for the activator MgADP was also determined.  The K1/2 for F6P was 
measured at various concentrations of MgADP and no significant change was observed 
(data not shown).  Therefore a competition experiment was performed in which the 
binding of PEP was determined at various concentrations of MgADP (Figure 5-7A).  
From this experiment, the Kiyapp was determined at each concentration of MgADP and 
then plotted as a function of concentration of MgADP (Figure 5-7B).  From these data, it  
was determined that the binding affinity for MgADP to the allosteric binding site is 23  ± 
3 mM, which is similar to 28 ± 8 mM, exhibited by LbPFK (82).     
 
Discussion 
 The allosteric site of the non-allosteric LbPFK is the only part of the enzyme that 
is dramatically different when compared to the allosteric enzymes EcPFK, BsPFK and 
TtPFK.  Several key residues identified by Evans to be involved in MgADP and PG 
binding to BsPFK are not conserved in LbPFK and lack of these residues may cause the 
allosteric ligands to bind less tight to LbPFK compared to EcPFK, BsPFK and TtPFK 
(83, 84). To test the involvement of these key residues, mutations were made within the 
allosteric binding site changing amino acid residues from those found in LbPFK to those 
of TtPFK, which exhibits the tightest binding affinity for PEP of the three allosteric 
PFKs, BsPFK, EcPFK and TtPFK (78).  Upon changing the amino acid residues 55, 59, 
211, 214, 215 and 216 alone, no change was seen in the binding affinity for PEP.  There 
were also no significant changes in the binding of the substrates F6P and MgATP.  This  
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Figure 5-7.  PEP/MgADP competition assay for PFKs1s2 at 25°C, pH 8.0.  (A)  The K1/2 
for F6P was measured as a function of PEP and the data were fit to equation 3-3 to 
determine the Kiyapp for PEP at each [MgADP].  This was performed and plotted from 0 
to 10 mM MgADP with 0mM (pink), 1mM (purple), 5mM (blue) and 10mM (green).  
(B)  The Kiyapp for PEP was plotted as a function of MgADP and fit to equation 2-6 to 
determine the Kixapp for MgADP. 
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result indicates that more than one amino acid residue change is most likely needed to 
enhance binding for the inhibitor PEP to the allosteric site.   
 To test this hypothesis several residues were mutated at the same time.  Several 
of these combination mutants were unstable and a new approach was utilized in which a 
stretch of amino acid residues was changed simultaneously from the sequence found in 
LbPFK to that found in TtPFK.  The two areas chosen to study were residues 52-61 and 
206-218.  These sequences encompass the residues chosen in the single mutant study.  
The two single combination mutants PFKs1 and PFKs2 exhibited similar kinetic 
properties as LbPFK, most importantly with regard to binding of PEP to the allosteric 
site.  There was an enhancement in the Km for MgATP along with a weakening in F6P 
binding at the active site, which is approximately 17 Å away but these changes were 
very small when compared to LbPFK.  The binding of MgATP to the active site of 
TtPFK is extremely tight compared to LbPFK and according to these results the amino 
acids within the allosteric site don’t seem to be involved in this difference.   
 The two long cassette variants were combined to form PFKs1s2 which was the 
only mutant in this study to show any enhancement in PEP binding.  The dissociation 
constant for PEP was decreased by approximately a factor of 10.  Even with this 
enhancement in PEP binding saturation with PEP could not be reached and a coupling 
constant could not be determined.  Not reaching saturation with PEP indicates that the 
coupling between F6P and PEP is stronger than what is seen in TtPFK.  TtPFK has a Qay 
of 0.068 ± 0.02, which is the weakest PEP inhibition exhibited by TtPFK, BsPFK or 
EcPFK (78).  If the coupling in LbPFK is the same as that seen in TtPFK and based on 
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the definition of Qay, the concentration of PEP required to reach maximum saturation 
would be approximately 40 mM(74).  In these experiments the highest concentration of 
PEP used was 80 mM and it is therefore likely that PEP is a better inhibitor in PFKs1s2 
than in TtPFK.  The enhanced PEP binding in PFKs1s2 also suggests that both sides of 
the allosteric site must be changed in order for significant PEP binding to occur.  These 
mutations also introduce several positive charges which would be expected to help the 
negatively charged PEP bind tighter within the allosteric binding site. 
 From structural studies of BsPFK one of the regions that has been proposed to 
change position upon the binding of the inhibitor analog PG is a loop which contains 
residues 213-215 (84).  In the allosteric BsPFK and EcPFK, all three of these residues 
are positively charged but one of these charges is missing in LbPFK which may prevent 
this structural change from occurring.  TtPFK contains only two positive charges since 
residues 215 is a serine.  Across the interface are residues 55 and 59 which are also quite 
different in LbPFK compared to the allosteric PFKs.  The role of 55 is not clear since 
this residues is not well conserved between the four PFKs but 59 are interesting because 
LbPFK is the only PFK of the four which has a positively charged H in place of either a 
D or N.  In BsPFK, 59 and 215 are close enough to form a potential hydrogen bond 
when PG is bound, and this would not be possible in LbPFK since both of these residues 
are histidines.  This hydrogen is also not present in TtPFK since there is a N at position 
59 and a S at position 215.  Since TtPFK has tighter PEP binding than BsPFK, the 
hydrogen bond may not be involved in PEP binding, but there is evidence that it may be 
involved in allosteric inhibition (78).  These two regions are changed in the mutant 
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PFKs1s2 and having both sides of the allosteric site mutated at the same time might 
allow for any potential interactions across the interface to remain intact to allow for 
optimal PEP binding.   
 Another interesting characteristic of PFKs1s2 that is not seen in LbPFK is the 
change in nH as a function of PEP concentration.  This phenomenon is called 
heterotropically induced homotropic cooperativity and occurs when the binding of the 
effector causes a change in the magnitude of the coupling between the active sites (88).   
The change in the nH caused by effector binding is best explained using a dimer as an 
example.  Consider a dimer of monomers, each containing one active site and one 
allosteric site, which allow for both intrasubunit and intersubunit heterotropic couplings 
(Qay1 and Qay2).  There are also three homotropic couplings to consider; Qaa, Qaa/y and 
Qaa/yy which occur in the absence of effector, when one allosteric site is occupied or 
when two allosteric sites are occupied, respectively.  The values of any and all of these 
couplings can determine the effect the heterotropic ligand has on the homotropic 
coupling (88).   
In BsPFK, the change in nH is described as sub-saturating heterotropically 
induced homotropic cooperativity.   In this case, the effect of the allosteric ligand on the 
cooperativity of the substrate is close to unity when Y = 0 and when Y is saturating and 
reaches a maximum value at sub-saturating concentrations of Y (88).  The maximum 
number for nH reached is dependent on the magnitude of the heterotropic coupling so 
that the stronger the coupling, the greater the change in nH.  Sub-saturating 
heterotropically induced homotropic cooperativity is not seen with TtPFK where nH 
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starts out around 1.5 and then begins to increase once PEP binds reaching a maximum 
value of 2.5 at saturating concentrations of Y (78).  In this case, the effect on nH at 0 and 
saturating PEP are not equal.  The effect on nH by PEP seen in PFKs1s2 could 
potentially be explained by either mechanism but since saturation with PEP cannot be 
reached, the actual mechanism is hard to determine.  It is clear that the effect of PEP on 
F6P binding is stronger in PFKs1s2 than in TtPFK in Figure 4-3.  Since the allosteric 
sites are very similar between the mutant and TtPFK these differences may arise from 
differences found in other regions of the enzyme.     
 Even though there was an enhancement in the binding affinity for PEP to the 
allosteric site of PFKs1s2, the same was not true for the activator MgADP.  PFKs1s2 
binds PEP 8.5-fold tighter than MgADP, which binds with the same affinity as LbPFK 
(82).   This difference in binding most likely is due to the lack of the residues needed to 
properly bind MgADP.  In EcPFK, MgADP interacts with several residues including 
E187, D59, and R21, R25, R54 and R154 (83).  Of these residues the only one which 
was modified was 59, which in LbPFK is an H and in PFKs1s2 was changed to a N.  In 
the case of the other residues, PFKs1s2 contains R21, R25 and R154, a V at 54 and a D 
at 187.  The shorter side-chain of aspartate might weaken the interaction between 187 
and the Mg ion of MgADP.  Therefore, it might be necessary to introduce D187E along 
with the other residues to enhance MgADP binding to the allosteric site of LbPFK.   
Another possible reason for weak binding of MgADP are the differences at 
positions 59 and 154.  In PFKs1s2 there is a N at 59 rather than the aD that is present in 
EcPFK and BsPFK.  The D hydrogen bond with the –OH of the adenosine ring of 
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MgADP.  A N could not form this potential interaction as it would be unable to accept 
the hydrogen from the oxygen.  In EcPFK, R154 forms two potential hydrogen bonds 
with the β-phosphate of MgADP and these hydrogen bonds would not be present 
PFKs1s2 due to the V at position 154.  However, there is a V at position 54 in BsPFK 
and MgADP still binds to the allosteric site even without these interactions.  Instead, 
R211 takes the place of V154 in the interactions with MgADP, and PFKs1s2 contains an 
R211 which could potentially take the place of R154 as is seen in BsPFK (83).  Not 
changing these residues in combination with those already mutated in PFKs1s2 might 
explain the differences seen between binding affinities of PEP and MgADP to the 
allosteric site.          
 In conclusion, the multiple amino acid differences within the allosteric binding 
site of LbPFK and the absence of many positively charged residues are likely involved 
in the weak binding affinity of the allosteric inhibitor PEP.  This is further evident when 
these residues are mutated simultaneously from the residues in LbPFK to those in 
TtPFK, which has the tightest PEP binding compared to other allosteric bacterial PFKs 
studied.  Modifying residues 55, 59, 211, 213, 214, 215 and 216 enhanced PEP binding 
but in order to fully understand how these residues enhanced PEP binding a crystal 
structure of PFKs1s2 must be solved.  
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CHAPTER VI 
INTRODUCING ALLOSTERIC INHIBITION IN LbPFK BY COMBINING 
MUTATIONS FROM REMOTE REGIONS 
 
 In most bacteria, phosphofructokinase (PFK) is an allosterically regulated 
enzyme which binds the inhibitor phospho(enol)pyruvate (PEP) and the activator 
MgADP.  However in the bacterium Lactobacillus delbrueckii subspecies bulgaricus, 
PFK (LbPFK) exhibits weak binding affinity for both PEP and MgADP and therefore 
presumably will not be allosterically regulated by these ligands in the cell (82).  PFK 
catalyzes the first committed step in glycolysis transferring a phosphoryl group from 
MgATP to fructose-6-phosphate (F6P) forming fructose-1,6-bisphosphate (FBP) and 
MgADP.  Bacterial PFKs are structured as homotetramers that contain four active sites 
and four allosteric sites.  These sites are located along the dimer-dimer interfaces with 
the active sites along one dimer-dimer interface and the allosteric sites along the other 
dimer-dimer interface.  For those PFKs that respond, binding of either PEP or MgADP 
to the allosteric binding site will cause a change in the binding affinity for the substrate 
F6P at the active site with no change in the catalytic rate, so PEP and MgADP are 
considered K-type allosteric effectors. 
 LbPFK shows high sequence identity to three known allosterically regulated 
PFKs, those from E. coli (EcPFK), Bacillus stearothermophilus (BsPFK) and Thermus 
thermophilus (TtPFK).  LbPFK shows 56% identity to BsPFK, 47% identity to EcPFK 
and 46% identity to TtPFK.  In 2005, the first crystal structure of LbPFK was solved to 
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1.86 Å resolution and a structural comparison between LbPFK and known structures 
from EcPFK and BsPFK was performed.  This comparison indicates an overall 
conservation in secondary, tertiary and quaternary structure (82-84, 94, 95).  The 
allosteric site residues are not well conserved compared to the other allosterically 
regulated PFK.  The lack of conservation within the allosteric binding site was 
considered to be a reason for the weak binding for both PEP and MgADP to LbPFK. 
 Of the three allosterically regulated PFKs, TtPFK exhibits the tightest binding to 
the inhibitor PEP with a Kiy° equal to 3µM (78).  LbPFK binds PEP 9,000-fold tighter 
than TtPFK (Kiy° = 27mM).  For this reason, residues within the allosteric site of LbPFK 
were changed to the corresponding residues in TtPFK.  Since no crystal structure of 
TtPFK has been solved, BsPFK was used in structure comparisons to identify which 
residues to target for mutagenesis studies.  Residues 55, 59, 211, 214, and 215 were 
targeted based on the lack on conservation as well as proximity to the allosteric binding 
site.  Several of these residues have also been identified in the literature as being 
involved in the binding of either PEP or MgADP to the allosteric binding site (84, 85, 
111).  Both individual mutations as well as long cassette mutations were created that 
contained the stretches of residues 52-61(PFKs1) and 206-218 (PFKs2).  It was only 
when the two large cassette mutations were combined to form PFKs1s2 that PEP binding 
was enhanced 10-fold compared to LbPFK.  The binding of MgADP to PFKs1s2 
exhibited no change from wild-type (Kix° = 24mM) which indicates that more mutations 
within the allosteric site are needed for MgADP to bind to LbPFK with higher affinity. 
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Another region that has been identified to be important in PEP binding to BsPFK 
is along the active site interface and involves the 100% conserved residue D12 (73, 85).  
D12 is located 15 Å away from the closest allosteric site, and changing D12 to an 
alanine (D12A) enhances PEP binding to BsPFK 100-fold compared to wild-type.  
D12A was also introduced in LbPFK and enhanced binding for PEP 9-fold compared to 
WT LbPFK (see Chapter IV).  In BsPFK the effect of D12A has been correlated to 
structural changes within PFK upon this mutation that involve both a 7° quaternary shift 
as well as the unwinding of a helix located along the active site interface across from 
D12 (85).  D12A LbPFK was crystallized to 2.4 Å resolution and comparisons to the 
structure of wild-type LbPFK indicate no major changes between the two structures.  
Lack of the structural changes upon the D12A mutation in LbPFK compared to those 
seen in D12A BsPFK may indicate why there is only a 9-fold change in PEP binding 
compared to the 100-fold seen in BsPFK. 
 D12A LbPFK exhibited not only enhanced binding of PEP to the allosteric site 
but enhanced binding of the activator MgADP as well.  MgADP binds weakly to LbPFK 
and causes inhibition as high concentration (≥ 5mM) compared to the activation seen in 
EcPFK.  In D12A LbPFK, MgADP binding is enhanced 9-fold and still appears to act as 
an inhibitor.  The MgADP inhibition might be due to dead end product inhibition since 
MgADP is a product of the reaction, but since MgATP is saturating throughout the 
experiment this mechanism is highly unlikely.  Therefore, MgADP appears to be acting 
as an allosteric inhibitor of LbPFK, and this inhibition is more evident in D12A LbPFK 
due to the enhanced binding for MgADP at the allosteric site.  
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The lack of conservation within the allosteric site may be a reason for the smaller 
enhancement in binding of the allosteric ligands exhibited by D12A LbPFK compared to 
BsPFK.  Therefore the large cassette mutations encompassing the allosteric site were 
combined with D12A in LbPFK in an attempt to further enhance the binding for the 
allosteric ligands.  The combination mutant (PFKs1s2D12A) binds PEP with a 
dissociation constant equal to 1.3 mM, which is 21-fold tighter than LbPFK.  Moreover 
MgADP exhibits a Kix° equal to 3.4 mM, an 8-fold enhancement compared to LbPFK.  
PEP binding to PFKs1s2D12A appears to show a nearly additive effect between the two 
regions since PFKs1s2 exhibits a 10-fold effect and D12A a 9-fold effect.  Binding for 
MgADP seems to be due to the mutation D12A since no further enhancement was 
measured upon combining the two regions.  Therefore, other residues in the allosteric 
site need to be changed in order for further enhancement in MgADP binding to be 
observed. 
Along with the enhancement in PEP binding in PFKs1s2D12A, allosteric 
inhibition was quantified for the first time in a variant of LbPFK.  A coupling constant 
(Qay) equal to 0.007 ± 0.0008 was measured for PFKs1s2D12A, and this value is 2-fold 
less than that seen in EcPFK (Qay = 0.016 ± 0.003), 7-fold greater than that in BsPFK 
(Qay = 0.001 ± 0.0001) and 9-fold less than that seen in TtPFK (Qay = 0.068 ± 0.002) 
(72, 78, 81).  Therefore, it is evident that through mutations within two distinct and 
remote regions of LbPFK, binding for the allosteric ligands PEP and MgADP has been 
enhanced allowing the nature and magnitude of the allosteric inhibition to be quantified 
for the first time in a variant of LbPFK. 
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Methods 
Site-directed Mutagenesis 
 The strategy employed for site-directed mutagenesis is similar to that discussed 
in Chapter II.  PFKs1s2D12A was created by using pKK223-3/PFK containing the 
mutation PFKs1s2 as the parent plasmid and introducing D12A using the 
oligonucleotide pair presented in Chapter IV. 
 
Purification of Tt/Lb 2 + D12A 
 PFKs1s2D12A was purified using the protocol for D12A LbPFK with the 
following exceptions.  After pooling fractions with PFK activity off the 100 mL 
Mimetic-Blue A column, the sample was concentrated to 20 mL with PEG 
(polyethyleneglycol), dialyzed into Buffer A-1 (20mM Tris-HCl, pH 8.5, 0.1mM EDTA, 
1mM F6P) and loaded onto a 20 mL anion-exchange HighQ column at 1mL/min, 4°C.  
A 0-1mM NaCl gradient was applied to the HighQ column and 1 mL fractions were 
collected.  The fractions containing PFK activity were pooled, dialyzed into Buffer A-1 
+ 5mM MgCl2 and stored at 4°C.  Protein purity was assessed using SDS-Page, and the 
concentration was determined using the BCA protein assay. 
 
Results 
 Two distinct regions of LbPFK were targeted for mutagenesis in order to 
enhance binding for the allosteric inhibitor PEP in LbPFK, the allosteric binding site and 
the active site interface region surrounding D12A.  Within the allosteric binding site, two 
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large cassettes of mutations were created that contain residues 52-61 and 206-218 and 
these stretches of residues are located across the interface from one another and make up 
the allosteric site along with several conserved arginines.  Due to the tight binding 
affinity for PEP to TtPFK, these cassettes of residues were mutated from the residues in 
LbPFK to the corresponding residues in TtPFK.  In LbPFK, 52-61 contains the residues 
52-L E S E D V A H L I -61 and was mutated to the residues in TtPFK 52-L G V R D V 
G N I I -61 to create PFKs1.  LbPFK 206-218 contains the residues 206- K Q A Q E S G 
K D H G L V -218 and was mutated to the TtPFK sequence 206- E A S Q R R G K K S 
S I V-218 to create PFKs2.  When these two cassettes were combined to form PFKs1s2 
binding for PEP to the allosteric site was enhanced 10-fold compared to WT LbPFK 
(Figure 6-3, Table 6-1).  However, these mutations had no effect on MgADP binding to 
the allosteric site.  A complete examination for PFKs1s2 is found in Chapter V.  
 D12A was also introduced into LbPFK and enhanced binding for both PEP and 
MgADP 9-fold compared to LbPFK.  D12 is located along the active site interface, 15 Å 
from the nearest allosteric binding site yet effects binding to that site from this distance 
(Figure 6-1).  Due to the effects of both D12A and PFKs1s2, the two mutations were 
combined to form PFKs1s2D12A, and the binding affinities for both the substrates as 
well as the allosteric ligands were determined.   Figure 6-2 shows the titration curves for 
the substrates F6P and MgATP for PFKs1s2D12A compared to LbPFK as well as 
PFKs1s2 and D12A.  Due to the dramatic differences in specific activity for these 
mutants, the rates were normalized to the specific activity given in Table 6-1.  
PFKs1s2D12A has weaker F6P binding but a lower Kb for MgATP binding compared to  
 117 
 
Figure 6-1.  Distances between D12 and allosteric site phosphates in LbPFK crystal 
structure.  In the crystal structure for LbPFK, the distances between D12 (yellow) and 
each of the four phosphates bound to the four allosteric binding sites (white) were 
measured using UCSF-Chimera®.  Each distance is highlighted in green with the 
distance given in Å.   
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both wild-type and PFKs1s2, with similar binding affinities as D12A.  Therefore the 
changes in the binding affinities for F6P and MgATP for PFKs1s2D12A are due more to 
the D12A mutation than to the allosteric site mutations.   
 To determine the binding affinity for the allosteric ligands, the K1/2 for F6P was 
measured at various concentrations of PEP or MgADP and then plotted as a function of 
the allosteric ligand concentration (Figure 6-3).  PEP binds to PFKs1s2D12A with an 
affinity of 1.3 mM and MgADP with an affinity of 3.4 mM.  Compared to LbPFK, the 
binding to PFKs1s2D12A is 21-fold tighter for PEP and 8-fold tighter for MgADP.  The 
21-fold effect on PEP binding exhibited by PFKs1s2D12A is nearly additive given the 
10-fold effect of PFKs1s2 and the 9-fold effect of D12A.  Enhancing PEP binding 21-
fold allowed for a coupling constant, Qay, to be determined for PEP inhibition (Qay = 
0.007 ± 0.0008).  Qay for PFKs1s2D12A is 2-fold stronger than that of EcPFK (Qay = 
0.016 ± 0.003) (72).  MgADP binding to PFKs1s2D12A is similar to D12A but tighter 
than both wild-type and PFKs1s2 so the effect on MgADP binding is due to the D12A 
mutation.  MgADP is also an inhibitor of all three variants as well as wild-type, which is 
opposite the effect seen in other PFKs such as EcPFK and TtPFK (78, 80). 
Since MgADP is a product of the PFK reaction and to ensure that the binding for 
MgADP determined from the coupling experiments is to the allosteric site and not to the 
active site, a competition experiment was performed where the apparent binding affinity 
for PEP (Kiyapp) was determined at various concentrations of MgADP.  MgATP was at a 
saturating concentration throughout these experiments as well as phosphocreatine and  
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Figure 6-2.  Substrate titration curves for wild-type LbPFK vs. LbPFK variants at 25°C, 
pH 8.0.  (A) F6P titration curves for LbPFK (pink), PFKs1s2 (green), D12A (blue) and 
PFKs1s2D12A (purple).  Experiment was performed at [MgATP] = 15 mM for LbPFK, 
10mM for PFKs1s2 and 3mM for both D12A and PFKs1s2D12A.  All data were fit to 
equation 2-1.  (B)  MgATP titration curves for LbPFK (pink), PFKs1s2 (green), D12A 
(blue) and PFKs1s2D12A (purple).  Experiment was performed at [F6P] = 3mM for 
LbPFK and PFKs1s2 and 5mM for D12A and PFKs1s2D12A.  All data were fit to 
equation 2-2.  In both experiments, the specific activity was normalized for each PFK to 
the appropriate Vmax from Table 5-2.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
Table 6-1.  Steady state kinetic paremeters for wild-type and LbPFK variants at 25°C, pH 8.0 
. 
LbPFK S.A. 
(U/mg)
a 
Kb (mM)
b 
Kia° (mM)
c 
Kiy° 
(mM)
c 
Kix° 
(mM)
c,d 
Qay
c 
WT 250 0.34 ± 0.4 0.025 ± 0.0001 27 ± 2 28 ± 8 N.A. 
PFKs1s2 240 0.27 ± 0.01 0.039 ± 0.003 2.8 ± 0.1  32 ± 6 N.A. 
D12A 30 0.049 ± 0.003 0.17 ± 0.02 3.0 ± 0.1 2.6 ± 0.2 N.A. 
PFKs1s2D12A 12 0.025 ± 0.002 0.26 ± 0.02 1.3 ± 0.05 3.4 ± 0.2 0.007 ± 0.0008 
a S.A.= Specific activity. b Kb for MgATP was determined at [F6P] = 3mM for WT 
LbPFK and Tt/Lb 2 and 5mM for D12A and Tt/Lb 2 + D12A. c Values were determined 
at [MgATP] = 15mM for WT LbPFK, 10mM for Tt/Lb 2 and 3mM for D12A and Tt/Lb 
2 + D12A. d Kix° for LbPFK from (82). 
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Figure 6-3.  Binding and allosteric response of PEP and MgADP for wild-type and 
LbPFK variants at 25°C, pH 8.0.  The K1/2 for F6P was measured at various 
concentrations of (A) PEP or (B) MgADP for LbPFK (pink), PFKs1s2 (green), D12A 
(blue) and PFKs1s2D12A (purple).  Each measurement was determined at [MgATP] = 
15 mM for LbPFK, 10mM for PFKs1s2 and 3mM for D12A and PFKs1s2D12A.  All 
data were fit to equation 2-4 except for PFKs1s2D12A PEP binding was fit to equation 
2-3 to determine values given in Table 6-1 and 6-2.  MgADP data for LbPFK from (82). 
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Figure 6-4.  PEP/MgADP competition assay for LbPFK variants at 25 °C, pH 8.0.   The 
K1/2 for F6P was measured as a function of PEP and the data were fit to equation 2-3 
(PFKs1s2 and D12A) or 2-4 (PFKs1s2D12A) to determine the Ki,app for PEP at each 
[MgADP] for PFKs1s2 (green), D12A (blue) and PFKs1s2D12A (purple).  The apparent 
Ki for PEP (Kiyapp) was plotted as a function of MgADP and fit to equation 2-6 to 
determine the apparent Ki for MgADP (Kixapp) to give values in Table 6-2. 
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Table 6-2.  Determination of Ki for MgADP and PEP for wild-type  and LbPFK variants 
at 25°C, pH 8.0
 
LbPFK Kix° (mM)
a,b,c 
Kix
app
 (mM)
b,d,e 
Kiy° (mM)
b,c 
Kiy
app
 (mM)
b,d,e 
WT 28 ± 8 N.D. 27 ± 2 N.D. 
PFKs1s2 32 ± 6 23 ± 3 2.8 ± 0.1  2.7 ± 0.05 
D12A 2.6 ± 0.2 4.5 ± 0.4 3.0 ± 0.1 2.9 ± 0.09 
PFKs1s2D12A 3.4 ± 0.2 4.5 ± 0.3 1.3 ± 0.05 1.3 ± 0.03 
a Kix° for WT from (82).  b Values determined at [MgATP] = 15mM for LbPFK, 10mM 
for PFKs1s2 and 3mM for D12A and PFKs1s2D12A.  c Values determined from 
coupling experiments between F6P and either PEP or MgADP.  d Values determined 
from competition experiment between PEP and MgADP.  e N.D. = not determined. 
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creatine kinase being present which would regenerate any MgADP formed from the 
reaction to MgATP.  Figure 6-4 is a replot of the Kiyapp as a function of MgADP and 
fitting of the data to equation 2-6 the Ki for MgADP (Kixapp) was determined for D12A, 
PFKs1s2 and PFKs1s2D12A.  Table 6-2 compares the values for PEP and MgADP 
binding to the allosteric site from the two types of experiments and these numbers 
compare nicely indicating that the values for MgADP binding, as well as PEP binding, 
determined from the coupling experiments is measuring binding to the allosteric site.  
 Values for MgADP determined from the competition experiment with PEP are 
slightly weaker than that determined from the coupling experiments which might 
indicate that the inhibition measured in the coupling experiment could be a combination 
of both product and allosteric inhibition.  Therefore, the binding affinity for MgADP to 
the active site was determined by measuring the Kb for MgATP at various concentrations 
of MgADP for PFKs1s2D12A (Figure 6-5A).  By fitting the data to equation 2-4 a 
binding affinity for MgADP to the active site of 0.29 ± 0.02 mM was determined, 12-
fold tighter than the binding affinity for MgADP at the allosteric site.  The value for 
MgADP binding determined from the competition experiment between PEP and 
MgADP is much closer to the value of MgADP binding at the allosteric site than it is to 
the value for the active site.  These results indicate that the inhibition measured in the 
coupling experiment between MgADP and F6P is due to the binding of MgADP at the 
allosteric site and not product inhibition.  
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Figure 6-5.  Effect of MgADP on binding of MgATP at the active site at 25°C, pH 8.0.  
(A) The Kb for MgATP was measured at various concentrations of MgADP and plotted 
as a function of [MgADP].  Data were fit to equation 2-4 to determine a Ki for MgADP 
at the active site of 0.29 ± 0.02 mM.  (B) A double-reciprocal plot of initial velocity (ν) 
versus MgATP concentrations at the following MgADP concentrations: 0.04mM 
(purple), 0.156mM (blue), 0.313mM (dark green), 0.625mM (pink), 1.25mM (cyan), 
2.5mM (light green) and 5mM (orange).  Data were plotted to a linear equation to find 
the slope and intercept at each [MgADP].  (C) Replot of the slope (purple) and intercept 
(green) as a function of [MgADP].   
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Titrations curves for MgATP at [MgADP] from 0.04 to 5mM were plotted using 
a  double-reciprocal plot of initial velocity (ν) versus MgATP concentration (Figure 6-
5B) and the pattern indicates a non-competitive relationship between MgATP and 
MgADP (115).  In EcPFK, MgADP and MgATP have a competitive relationship which 
is described by a random kinetic mechanism at sub-saturating concentrations of F6P (91, 
114, 116).  In a random kinetic mechanism, saturating with substrate A will cause 
substrate B and the corresponding product Q to bind to different forms of the enzyme.  
The binding of B and Q to different forms of the enzyme will cause an change in the 
intercept and along with the change in slope, would give a non-competitive relationship 
between B and Q (115).  Therefore, the non-competitive relationship between MgATP 
and MgADP in LbPFK could be explained simply by having saturating concentrations of 
F6P.  Therefore, the dissociation constant determined for MgADP in the 
MgATP/MgADP experiment is likely to be at the active site, which is much tighter than 
that measured at the allosteric site (Figure 6-4 and 6-5).  Comparing the dissociation 
constants for MgADP at both the active site and allosteric site indicate that the inhibition 
of F6P by MgADP is more likely to be allosteric inhibition than product inhibition. 
 
Discussion 
 Two remote regions within the non-allosteric LbPFK were mutated in order to 
enhance binding affinity for the allosteric ligands PEP and MgADP.  First, the allosteric 
binding site was targeted based on this region being the least conserved region when 
comparing LbPFK to the known allosteric PFKs, EcPFK, BsPFK and TtPFK.  Residues 
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within the large cassettes 52-61 and 206-218 were changed from the sequence of LbPFK 
to the corresponding sequence of TtPFK.  PFKs1s2 enhanced binding affinity of PEP 
10-fold compared to WT LbPFK with no enhancement for the activator MgADP (see 
Chapter V).  D12, located 15 Å away from the nearest allosteric site and along the active 
site interface, was changed to an alanine and enhanced binding for both PEP and 
MgADP 9-fold compared to LbPFK (see Chapter IV).  Finally, combining both 
mutations to form PFKs1s2D12A caused a 21-fold enhancement in PEP binding that 
appears to be additive as it combines the 10-fold enhancement from Tt/Lb 2 with the 9-
fold enhancement from D12A.  The 21-fold enhancement in PEP binding was 
accompanied by a Qay = 0.007 ± 0.0008 and this is the first time the inhibition of PEP 
has been quantified in the non-allosteric LbPFK. 
 Inhibition by PEP in PFKs1s2D12A is approximately 2-fold stronger than 
EcPFK (Qay = 0.016 ± 0.003), 10-fold stronger than TtPFK (Qay = 0.068 ± 0.002) even 
though the binding for PEP to Tt/Lb 2 + D12A is much weaker than either EcPFK or 
TtPFK (72, 78, 81).  In 1991, La Bras did the first kinetic analysis of LbPFK and 
indicated that LbPFK is a non-allosteric PFK (97).  However from the current study it is 
clear that LbPFK is an allosteric form of PFK with weak binding affinity for the 
allosteric ligands PEP and MgADP, though likely causing little allosteric control in the 
cell.  It is possible that Lactobacillus delbrueckii subspecies bulgaricus no longer 
requires the allosteric regulation of PFK since it only metabolizes four sugars and the 
main role of its metabolism is to form lactic acid (97).  There is evidence of an 
allosterically regulated glyceraldehydes-3-phosphoate dehydrogenase in Lactobacillus 
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delbrueckii subspecies bulgaricus and this could potentially be a more efficient way to 
regulate glycolysis in the lactic acid bacteria (56).  However the weak binding for both 
PEP and MgADP make LbPFK a great template in better understanding of phenomenon 
of allostery.    
   Not only did PFKs1s2D12A have enhanced binding for the inhibitor PEP, it also 
exhibited 8-fold tighter binding for MgADP compared to WT LbPFK.  PFKs1s2 had 
similar binding for MgADP as LbPFK but D12A showed a 9-fold enhanced binding for 
MgADP (see Chapters IV and V), indicating the change in MgADP binding to also be 
additive.  Even more interesting than the enhanced binding for MgADP is the inhibitory 
effect by MgADP since MgADP acts as an activator in EcPFK.  MgADP is also a 
product of the reaction, therefore it was important to ensure that the inhibition being 
measured is not product inhibition.  Several approaches were taken and together indicate 
that the binding affinity measured at the allosteric site is much weaker than that for the 
active site and the inhibition of F6P binding by MgADP is an allosteric effect.  The role 
of allosteric inhibition by MgADP in Lactobacillus delbrueckii subspecies bulgaricus is 
unclear but would likely not be seen in the cell due to the extremely weak binding for 
MgADP to LbPFK. 
 In conclusion, the current study indicates that the weak binding for PEP and 
MgADP to the allosteric binding site of LbPFK can be overcome by introducing changes 
within the residues in the allosteric site along with D12A into LbPFK.  Mutating both 
regions within LbPFK causes enhanced binding for both allosteric ligands, though to 
different extents, and each region is responsible for its own contribution of the binding 
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affinity.  Since no crystal structure has been solved for PFKs1s2D12A it is unclear how 
the mutations within each region affect the binding for PEP and MgADP and whether 
the changes in the binding affinities are even due to large structural changes or smaller 
dynamic changes.  Further studies of PFKs1s2D12A are needed to not only define the 
reason for the enhancement in binding affinities but also to determine the minimum 
number of mutations required for the observed enhancement. 
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CHAPTER VII 
SUMMARY 
 
 Phosphofructokinase (PFK) from the bacteria E. coli (EcPFK), Bacillus 
stearothermophilus (BsPFK) and Thermus thermophilus (TtPFK) is allosterically 
regulated by the inhibitor phospho(enol)pyruvate (PEP) and the activator MgADP.  
However, PFK from Lactobacillus delbrueckii subspecies bulgaricus (LbPFK) is non-
allosteric PFK due to weak binding for both PEP and MgADP, approximately 27 mM 
for both ligands.  Comparisons of the structures and sequences between LbPFK and the 
allosteric EcPFK and BsPFK show an overall conservation in structure and high 
sequence identity (47% identity with EcPFK and 56% identity with BsPFK) with the 
exception of the allosteric binding site.  LbPFK, like EcPFK, BsPFK and TtPFK, is a 
homotetramer formed as a dimer-of-dimers.  Along one dimer-dimer interfaces are the 
active sites and the allosteric sites along the other dimer-dimer interface.  Another region 
identified in the Reinhart lab to be involved in PEP binding to BsPFK is along 
surrounding the 100% conserved D12 (73, 85).  D12 interacts with various residues, 
including T156 and H160 that are located across the active site interface from D12 as 
well as R252 which is located within the active site and also interacts with the substrate 
fructose-6-phosphate (F6P).  Mutating D12 to an alanine in BsPFK enhanced PEP 
binding 100-fold even though D12 is located 15 Å from the nearest allosteric binding 
site (85).  Structural studies with D12A BsPFK showed that a large quaternary shift 
along the active site interface occurred when D12A was introduced as well as smaller 
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secondary structural changes within the allosteric binding site and the region surround 
D12A (85).  In the current study mutations were introduced within the allosteric site as 
well as the region along the active site interface that includes D12, T156 and H160 to 
better understand the weak binding for PEP and MgADP in LbPFK.         
 First, two new structures of LbPFK were solved to add to the structural library of 
bacterial PFKs.  The first structure was solved to 1.83 Å resolution and has phosphates 
bound to all four active sites, all four allosteric sites and one on the surface of each 
monomer.   There is also a chloride ion bound to the four active sites.  The surface 
phosphates and chloride ions are most likely due to the crystallization conditions which 
included MgCl2 and ammonium mono-phosphate.  The second structure was solved to 
2.2 Å resolution and has phosphate bound to the same locations as the first structure with 
the differences being F6P bound to the four active sites as well as a magnesium ion in 
the place of the chloride ion.  As with the first structure, the surface phosphates and 
magnesium ions are due to the crystallization conditions.  The two new structures of 
LbPFK are similar in overall secondary, tertiary and quaternary structure to the sulfate-
bound LbPFK structure published in 2005 (82).  Only the B-factor, which is a 
measurement of how much an atom oscillates or vibrates around the position specified 
by the model, is different between the two structures.  The phosphate-bound LbPFK is 
much more flexible overall compared to the substrate-bound LbPFK.  The increased 
rigidity in structure upon F6P binding if LbPFK is opposite from what is seen in BsPFK 
where the F6P bound structure is the most flexible when comparing the substrate-bound, 
apo and inhibitor-bound structures (85).  These two new structures of LbPFK are a more 
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useful comparison to the other bacterial PFK structures which have F6P and phosphate 
bound, which is a more physiologically relevant ion compared to sulfate. 
 Next, a mutagenesis study was performed on the D12 as well as the surrounding 
residues in LbPFK.  D12 was mutated to an alanine in LbPFK and enhanced binding for 
both PEP and MgADP 9-fold compared to LbPFK.  The change in PEP binding was 
weaker compared to that seen in BsPFK, so a crystal structure was solved of D12A 
LbPFK to 2.2 Å resolution.  D12A LbPFK contained sulfates bound to the four active 
sites, four allosteric sites and one on the surface of each monomer.  The presence of the 
sulfate on the surface of each monomer is likely due to the high concentration of 
ammonium sulfate in the crystallization conditions.  No major structural changes were 
observed upon comparing the structures of D12A LbPFK and the sulfate-bound LbPFK.  
No structural change in opposite of the large structural change observed in BsPFK upon 
the mutation D12A.  The lack of large structural perturbations might explain the smaller 
enhancement in PEP binding for D12A LbPFK compared to D12A BsPFK. 
 T156 and H160 form hydrogen bonds with D12 across the active site interface 
and introducing D12A into LbPFK would break these hydrogen bonds.  The breaking of 
these bonds could be the reason for the enhanced PEP binding and so T156A and H160A 
were also introduced into LbPFK.  Neither T156A nor H160A showed an enhancement 
in PEP binding.  LbPFK contains a histidine at position 161, right next to the histidine at 
160, and to show that H161 was not taking the place for H160 when H160A was 
introduced, H161A LbPFK as well as H160A/H161A LbPFK were created.  Like T156A 
and H160A, H161A and H160A/H161A exhibited no enhancement in PEP binding when 
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compared to wild-type LbPFK.  Lack of enhanced PEP binding for these variants 
indicates that the breaking of the hydrogen bonds formed between D12 and T156 or D12 
and H160 is not the reason for the enhanced PEP binding seen in D12A LbPFK. 
 Another region that was focused on in the mutagenesis study of LbPFK was the 
allosteric site.  As mentioned previously, resides within the allosteric site are not 
conserved when comparing LbPFK to EcPFK, BsPFK and TtPFK.  Several of these 
residues were changed from the residues in LbPFK to the corresponding residue in 
TtPFK, since PEP binding to TtPFK is 9,000-fold tighter compared to LbPFK.  E55R, 
H59N, S211R, D214K, H215S and G216S were introduced into LbPFK with no 
enhancement in PEP binding.  Large cassette mutations were also utilized where large 
sequences of amino acids from LbPFK were substituted with the amino acid sequence 
from TtPFK.  Regions including residues 52-61 (PFKs1), 206-218 (PFKs2), as well as 
the combination of the two regions (PFKs1s2) were mutated.  PFKs1 and PFKs2, like 
the single mutants, showed no enhancement in PEP binding.  However, PFKs1s2 
exhibited PEP binding 10-fold tighter to LbPFK.  Due to the enhanced PEP binding in 
PFKs1s2, binding for MgADP was measured and found to be similar to LbPFK.  The 
results of the allosteric site variants indicate the need for multiple changes within the 
allosteric binding site in order to enhance binding for the allosteric inhibitor PEP and 
more changes are needed to enhance binding for MgADP. 
 Finally, the PFKs1s2 and D12A variants were combined to form PFKs1s2/D12A.  
By creating PFKs1s2/D12A, further enhancement in PEP binding was measured (21-fold 
compared to LbPFK).  Along with the 21-fold enhancement in PEP binding, a coupling 
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between PEP and F6P was measured for the first time in LbPFK (Qay = 0.007 ± 0.0008).  
The Qay for PFKs1s2/D12A is 7-fold weaker than the coupling measured in BsPFK (Qay 
= 0.001 ± 0.0001) but 2-fold stronger compared to EcPFK (Qay = 0.016 ± 0.003) and 9-
fold stronger compared to TtPFK (Qay = 0.068 ± 0.002) (72, 78, 81).  MgADP binding 
for PFKs1s2/D12A was similar to D12A LbPFK indicating that the enhancement in 
MgADP binding is due to the D12A mutation.  MgADP appears to act as an allosteric 
inhibitor in LbPFK.  Enhancing MgADP binding in D12A and PFKs1s2D12A allows 
that inhibition to be more evident, and the reason for this inhibition in LbPFK is unclear.  
MgADP is a product of the PFK reaction and does show product inhibition of the 
substrate MgATP, but the inhibition of F6P is clearly allosteric.  A crystal structure of 
PFKs1s2/D12A has not been determined but would be useful in better understanding the 
role of these mutations in the overall enhancement in binding and inhibition measured 
for both PEP and MgADP. 
 In conclusion, the crystal structures and mutagenesis studies performed on 
LbPFK indicate that there are remote regions within the enzyme that are important for 
binding of the allosteric ligands PEP and MgADP.  Multiple changes in the allosteric site 
are needed to enhance the binding for PEP signifying that the weak binding of PEP in 
LbPFK is due to numerous differences in the composition of residues, not just a single 
residue, in the allosteric site.  The role of D12A in enhancing the binding for PEP and 
MgADP is still unclear but is necessary for tighter binding to the allosteric site.  The 
distance between D12 and the allosteric site is far reaching and the pathway that is 
involved in linking the two sites in unknown.  From the studies of PFKs1s2/D12A, it is 
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clear that allosteric inhibition is possible in LbPFK if PEP and MgADP can bind to the 
allosteric binding site.  It is likely then that the weak binding of PEP and MgADP to 
wild-type LbPFK causes the lack of allosteric regulation in this enzyme and as long as 
PEP and MgADP can bind with high enough affinity, an allosteric response can be 
measured.  Identifying the role of each mutation in PFKs1s2/D12A is needed in order to 
truly understand the molecular basis of the enhanced PEP and MgADP binding 
compared to wild-type LbPFK.         
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